Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU754086B2 - Alkyl ketones as potent anti-cancer agents - Google Patents
[go: Go Back, main page]

AU754086B2 - Alkyl ketones as potent anti-cancer agents - Google Patents

Alkyl ketones as potent anti-cancer agents Download PDF

Info

Publication number
AU754086B2
AU754086B2 AU48459/99A AU4845999A AU754086B2 AU 754086 B2 AU754086 B2 AU 754086B2 AU 48459/99 A AU48459/99 A AU 48459/99A AU 4845999 A AU4845999 A AU 4845999A AU 754086 B2 AU754086 B2 AU 754086B2
Authority
AU
Australia
Prior art keywords
ketone
cysteine
cys
chioromethyl
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48459/99A
Other versions
AU4845999A (en
Inventor
Rama K. Narla
David A. Perry
Fatih M. Uckun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Publication of AU4845999A publication Critical patent/AU4845999A/en
Application granted granted Critical
Publication of AU754086B2 publication Critical patent/AU754086B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

WO 00/00469 PCT/US99/l 4758 1 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS Field of the Invention The present invention relates to alkyl ketone compounds effective for treating tumor cells and particularly effective to induce apoptosis in leukemia cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
Background of the Invention Cancer is a major disease that continues as one of the leading causes of death at any age. In the United States alone, it is anticipated that more than a half a million Americans will die of cancer in 1999. Currently, radiotherapy and chemotherapy are two important methods used in the treatment of cancer.
Considerable efforts are underway to develop new chemotherapeutic agents for more potent and specific anti-cancer therapy, presenting effective and efficient cytotoxicity against tumor cells, with minimal interference with normal cell function.
Accordingly, there is an urgent need for the development and analysis of novel, effective anti-cancer agents.
Summary of the Invention Novel alkyl ketone compounds have been found to be potent cytotoxic agents with potent activity against cancer cells. For example, certain alkyl ketone compounds were found to exhibit potent cytotoxic activity, particularly against human breast cancer and leukemic cell lines, at micromolar concentrations. These compounds were also effective in inhibiting adhesion and invasion by cancer cells.
Accordingly, the present invention includes novel compounds and compositions having potent cytotoxic activity. The present invention also includes methods for treating tumors by administering to a subject an effective amount of a compound of the invention to inhibit growth and/or induce apoptosis of tumor cells.
Compositions of the invention contain an effective cytotoxic or inhibitory amount of a compound.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/I 4758 2 The compounds of the invention have the following formula 1:
R
3 2
H
wherein p is an integer selected from 0 and 1; X is 0Oor S; R1 is H, hydroxyl, (C 1
C
30 alkyl, (C 1
CA
0 alkenyl, (C 1
C
30 haloalkyl, (C 1 I C 3 o) diazoalkyl, -CH 2
-NR
6 R 7 or -CH 2 wherein R 5 is independently aryl, (C 1
C
30 alkyl, (C 1
C
30 haloalkyl, (C 1
C
30 alkenyl, (C 1
C
30 diazoalkyl, (C 1
C
24 cycloalkyl, or
C
24 cycloalkenyl,
R
6 is independently H, (Cl CA 0 alkyl, (C 1
C
3 0 haloalkyl,
C
3 o) diazoalkyl, (C 1
C
3 o) alkenyl, (C 1
C
30 haloalkenyl, (C 1
C
24 cycloalkyl, or (C 1
C
24 cycloalkenyl; R' i -OR', R 8 is independently (C 1
C
30 alkyl, (C 1
C
30 haloalkyl, (C 1
C
30 diazoalkyl, (C 1
C
30 alkenyl, (C 1
C
3 0 haloalkenyl, (C 1
C
24 cycloalkyl, or (C 1
C
24 cycloalkenyl;
R
9 is independently (C 1
C
3 o) alkyl, (C 1
C
3 0 haloalkyl, (C 1
C
30 diazoalkyl, (C 1
CA
0 alkenyl, (C 1
C
30 haloalkenyl, (C 1
C
2 4 cycloalkyl,
(C
1
C
24 cycloalkenyl, or -R'()C0 2
H;
R1 0 is (C 1
C
3 o) alkyl or (C 1
C
3 0 alkenyl, R 2 is C 1 or C 2
CH
2 or CH 2
CH
2
R
3 is (C 1
CA
0 alkyl, (C 1
CA
0 haloalkyl, (C 1
C
30 alkenyl, (Cl
C
3 0 haloalkenyl, (C 1
C
24 cycloalkyl, (C 1
C
24 cycloalkenyl, (C 1
C
24 )aryl, anthroquinonylmethyl, naphthylmethyl, or -CR 1 2 SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 3 is independently (Cl C 30 alkyl, (Ci C 30 haloalkyl, (Ci
C
30 alkenyl, or (Ci C 30 haloalkenyl;
R
1 2 is aryl substituted methyl;
R
4 is H, -C(O)R 13 or -C(O)-O-R 1 4;
R
13 and R 14 are each independently (C 1
C
1 2 alkyl, (Cl C 12 haloalkyl, (C 1
C
12 alkenyl, (CI C 1 2 haloalkenyl, (C 3
C
12 cycloalkyl, or (C 3
C
12 cycloalkenyl; or a pharmaceutically acceptable acid addition salt thereof.
Preferred compounds of the invention are those where p is the integer 1, R' is a haloalkyl, R 2 is C 1
R
3 is a (Ci C 22 alkyl, and R 4 is acetyl. Most preferred is the compound N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131).
Brief Description of the Drawings Figure 1A is a graph showing survival of primary cancer cells taken from six children with leukemia and treated with different concentrations of compound HI-131 as a function of drug concentration.
Figure 1B is a graph showing mean survival as a function of drug concentration from the data of Figure 1A.
Figures 2A-2F show photographs of apoptosis induced by HI-131 in treated human Leukemia cells.
Figure 2A. NALM-6 control;Figure 2B. HI-131 treated NALM-6 cells; Figure 2C. UPN1 control; Figure 2D. HI-131 treated UPN1 cells; Figure 2E. UPN2 control; Figure 2F. HI-131 treated UPN2 cells.
Figure 3 is a bar graph showing induction of apoptosis by HI-131 in treated primary leukemic cells and established NALM-6 and MOLT-3 cell lines.
Figure 4 is a bar graph showing inhibition of invasive properties of human MDA-MB-231 breast cancer cells by HI-131.
Figure 5 is a graph showing inhibition of the invasive properties of human U373 (glioblastoma) brain tumor cells by HI-131.
Figure 6 is a graph showing inhibition of the adhesion of human MDA- MB-231 breast tumor cells by HI-131.
Figure 7 is a graph showing inhibition of the adhesion by human U373 (glioblastoma) cells by HI-131.
SUBSTITUTE SHEET (RULE 26) i Detailed Description of the Invention The present invention includes novel alkyl ketone compounds having potent activity as cytotoxic agents. The compounds of the invention are useful agents for inhibiting growth or inducing apoptosis in tumor cells, for example, leukemia and breast tumor cells.
Definitions All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.
As used herein, "alkyl", are both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. As a preferred embodiment. chains of 1 to 22 carbon atoms are included.
As used herein, "alkene", are both branched and straight chain aliphatic: hydrocarbon groups that have at least one double bond.
As used herein, "alkoxy", are, saturated and unsaturated, branched and straight chain aliphatic hydrocarbon groups having a specified number of carbon atoms where at least one carbon atom forms a single-bond to an oxygen atom.
As used herein "amine", are primary, secondary, and tertiary amines.
As used herein "halogen" or "halo" substituent are fluoro, chloro.
bromo. and iodo.
As used herein, "pharmaceutically acceptable salt thereof" is an acid addition salt or a base salt.
As used herein, "pharmaceutically acceptable carrier" is any material which, when combined with a compound of the invention, allows the compound to retain biological activity, such as the abiliry to induce apoptosis of leukemia or *o breast tumor cells, and is non-reactive with the subject's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsions.
and various types of wetting agents. Compositions comprising such carriers are formulated by well known conventional methods (see. for example, Remington's Pharmaceutical Sciences, Chapter 43, 14th Ed., Mack Publishing Co., Easton. PA).
"Substituted cycloalkyl" are cyclic hydrocarbons having substituents' including halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl. haloalkyl, haloalkenyl, and aryl.
"Substituted cycloalkenyl" are cyclic hydrocarbons having at least one double bond where substituents include halo, alk-vl. alkenyl. oxvlalkyl. oxyalkenyl, haloalkyl, haloalkenyl, and aryl.
"Substituted aryl" are aromatic hydrocarbons having substituents including hydroxyl1, amino, aminomethyl, halo, alkyl, alkenyl, oxvalk-yl, oxyalke2nyl, haloalkylI, haloalkenyl, and aryl.
"Treating" or "Treatment" in the context of this invention means the prevention or reduction in severity of symptoms or effects of a pathological condition. including prolonging life expectancy. In the context of cancer therapy, treatment is prevention of tumor growth, reduction of tumor size, enhanced rumor cell dedih. and increased apoptosis.
Compounds of the Invention The novel alkyl ketone compounds of the invention have the general structure represented by the following formula 1:
-R
3
R
1 H 0
I
wherein pis 0or 1; X is 0 or S;
.:R
1 is hydroxyl, (C 1
C
30 alkyl, (C 1
C
3 0 alkenyl, (Cl C 3 o) haloalkyl, (C 1
C
3 0) diazoalkyl, 0-C(O)R-5, -_NRR'or-H
-S
25R1 *wherein
R
5 is independently arkl (C 1
C
30 alkyl, C 30 haloalkyl, (C 1
C
3 o) alkenyl, (C 1
CA
0 diazoalkyl, (C 1
C
4 cycioalkyl, or
(C
1
C
24 cycloalkenyl, WO 00/00469 PCT/US99/1 4758 6 R 6 is independently H, (Cl C 30 alkyl, (C 1
C
3 o) haloalkyl, (C 1
C
30 diazoalkyl, (C 1
C
30 alkenyl, (C 1
C
30 haloalkenyl, (C 1
C
24 cycloalkyl, or (C 1
C
24 cycloalkenyl; R 7 is -OR', R 8 is independently CA 0 alkyl, (C 1
C
30 haloalkyl, C 30 diazoalkyl, (C 1
C
3 o) alkenyl, (C 1
C
30 haloalkenyl, (C 1
C
24 cycloalkyl, or (C I C 24 cycloalkenyl;
R
9 is independently (C 1
CA
0 alkyl, (Cl C 30 haloalkyl, C 30 diazoalkyl, (C 1
C
30 alkenyl, (C 1
C
30 haloalkenyl, (C 1
C
24 cycloalkyl,
(C
1 I C 24 cycloalkenyl, or -R1 0 C0 2
H;
Rio is C 3 o) alkyl or (C 1
C
30 alkenyl, R2 is C, or C 2
CH
2 or CH 2
CH
2 R 3 is C 30 alkyl, C 30 haloalkyl, (C 1
C
30 alkenyl,
C
30 haloalkenyl, C 24 cycloalkyl, (C 1
C
24 cycloalkenyl,
C
24 )aryl, anthroquinonylmethyl, naphthylmethyl, or -CR'1 2 is independently C 3 o) alkyl, C 30 haloalkyl,
C
30 alkenyl, or (C 1
C
30 haloalkenyl; R 12is aryl substituted methyl;
R
4 is H, -C(O)R 1 3 or CO- R14 R 1 3 and R 1 4 are each independently C1 2 alkyl, C1 2 haloalkyl, C 1 2 alkenyl, C, 2 haloalkenyl, (C 3
C,
2 cycloalkyl, or (C 3 C 1 2 cycloalkenyl; or a pharmaceutically acceptable acid addition salt thereof.
The compounds of formula I are useful for the treatment of cancer, particularly the treatment of leukemia and breast cancer. In the method of the SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 7 invention, a therapeutic amount of a compound of formula I is administered to a patient for the treatment of cancer.
A preferred compound of the invention has the structure of formula II: R3
X
2
R
4 ,HN/ RI
O
A preferred embodiment of the compound of Formula II is that shown as having formula III, where X is S, R 3 is dodecyl, and R 4 is acetyl:
S
O R2
H
3 C
H
H
(III)
R' is most preferably chloromethyl; R 2 is preferably CH 2
R
3 is preferably a
C
1 2 alkyl; R 4 is preferably acetyl; and X is preferably S. A most preferred compound of formula II is N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131).
Another embodiment of the invention is a compound of formula IV: SR2 0
(IV)
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT[US99/1 4758 Preferred compounds of the invention having potent anti-cancer affects are the following: S-trans- trans-F aresyl-mercaptoethyl diazomnethyl ketone (HI-83); N-Boc-S-famnesyl-Cys chioromethyl ketone (HI- 124); S-trans- trans-Farnesyl-2-mercaptoethyl chioromethyl ketone (HI- 125); N-Ac-S-(3-methyl-2-butenyl)-Cys chioromethyl ketone (HI- 128); N-Boc-S-dodecyl-Cys chioromethyl ketone (HI-129); N-Boc-Gly-S-trans-trans-farnesyl-Cys chioromethyl ketone (HI- 130); N-Ac-S-dodecyl-Cys chioromethyl ketone (HI- 13 1); N-Ac-S-pentyl-cysteine chioromethyl ketone (HI-224); N-Ac-S-pentadecyl-cysteine chioromethyl. ketone (HI-225); S-Dodecyl-Cys chioromethyl ketone hydrochloride (HI-252); N-Ac-S-heptyl-cysteine chioromethyl ketone (HI-263); N-Ac-S-dodecyl-Cys-H (HI-274); N-Ac-S-methyl-cysteine chioromethyl ketone (HI-3 14); N-Ac-S-undecyl-cysteine chioromethyl ketone (HI-32 1); N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348); N-Ac-S-trityl-cysteine chioromethyl ketone (HI-3 N-Ac-S-octyl-cysteine chioromethyl ketone (HI-3 52); N-Ac-S-tetradecyl-cysteine chioromethyl ketone (HI-3 54); N-Ac-S-hexyl-cysteine chioromethyl ketone (HI-3 57); N-Ac-S-butyl-cysteine chioromethyl ketone (H1I-3 63); N-Ac-S-nonyl-cysteine chioromethyl ketone (HI-3 64); N-Ac-S-hexadecyl-cysteine chioromethyl ketone (HI-366); N-Ac-S-trans- trans-fanesyl-Cys diazomethyl. ketone (HI-367); N-Ac-S-trans- trans-farnesyl-Cys chioromethyl ketone (HI-368); N-Ac-S-propyl-cysteine chioromethyl ketone (HI-3 69); N-Ac-S-decyl-cysteine chioromethyl ketone (HI-37 1); N-Ac-S-benzyloxycarbonyl-cysteine chioromethyl ketone (HI-3 89); N-Ac-S-2-naphthylmethyl-cysteine chioromethyl ketone (HI-3 92); N-9-Fluorenylmethyloxycarbonyl-S-dodecyl-cysteine chioromethyl ketone (HI- 398); N-Ac-S-allyl-cysteine chioromethyl ketone (HI-4 19); N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 9 N-Ac-O-dodecyl-serine chloromethyl ketone (HI-489); N-Trifluoroacetyl-S-dodecyl-cysteine chloromethyl ketone (HI-490); N-Benzoyl-S-dodecyl-cysteine chloromethyl ketone (HI-491).
The compounds of the invention are capable of forming both pharmaceutically acceptable acid addition and/or base salts. Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Also included are heavy metal salts such as for example silver, zinc, cobalt, and cerium. Examples of suitable amines are N,N'dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamene, N-methylglucamine, and procaine.
Pharmaceutically acceptable acid addition salts are formed with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic, and the like. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce either a mono or di, etc. salt in the conventional manner. The free base forms may be regenerated by treating the salt form with a base. For example, dilute solutions of aqueous base may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions are suitable for this purpose. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for the purposes of the invention.
Cytotoxic Compounds The compounds of the invention are effective cytotoxic agents, for example, against tumor cells such as leukemic and breast cancer cells. In the methods of the invention, the cytotoxic effects of alkyl ketone compounds are achieved by contacting cells, such as tumor cells, with micromolar amounts of the inhibitory compound. By way of example, a particularly useful anti-tumor agent isN-Ac-Sdodecyl-Cys chloromethyl ketone (HI-131) as shown in the Examples below.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 Tumor Treatment The compounds of the invention can be used in methods of tumor treatment, for example, by administering to a subject a compound of the invention in order to achieve an inhibition of tumor cell growth, a killing of tumor cells, induction of apoptosis, and/or increased patient survival time.
The cytotoxic compounds of the invention are suitable for use in mammals.
As used herein, "mammals" means any class of higher vertebrates that nourish their young with milk secreted by mammary glands, including, for example, humans, rabbits, and monkeys.
Apoptosis Apoptosis, or programmed cellular death, is an active process requiring new protein synthesis. Typically, the process requires ATP, involves new RNA and protein synthesis, and culminates in the activation of endogenous endonucleases that degrade the DNA of the cell, thereby destroying the genetic template required for cellular homeostasis. Apoptosis is observed in controlled deletion of cells during metamorphosis, differentiation, and general cell turnover and appears normally to be regulated by receptor-coupled events. For these reasons, apoptosis has been called "programmed cell death" or "cell suicide." While every cell likely has the genetic program to commit suicide, it is usually suppressed. Under normal circumstances, only those cells no longer required by the organism activate this self-destruction program.
Apoptotic cell death is characterized by plasma membrane blebbing, cell volume loss, nuclear condensation, and endonucleolytic degradation of DNA at nucleosome intervals. Loss of plasma membrane integrity is a relatively late event in apoptosis, unlike the form of cell death termed necrosis, which can be caused by hypoxia and exposure to certain toxins and which is typically characterized, early-on by increased membrane permeability and cell rupture. As demonstrated in the Examples, the alkyl ketone compounds of the invention are effective agents for inducing apoptosis in tumor cells.
Administration Methods The compounds of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, including a human patient, in a SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 11 variety of forms adapted to the chosen route of administration. The compounds are preferably administered in combination with a pharmaceutically acceptable carrier, and may be combined with or conjugated to specific delivery agents, including targeting antibodies and/or cytokines.
The compounds can be administered by known techniques, such as orally, parentally (including subcutaneous injection, intravenous, intramuscular, intrasternal or infusion techniques), by inhalation spray, topically, by absorption through a mucous membrane, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants or vehicles.
Pharmaceutical compositions of the invention can be in the form of suspensions or tablets suitable for oral administration, nasal sprays, creams, sterile injectable preparations, such as sterile injectable aqueous or oleagenous suspensions or suppositories.
For oral administration as a suspension, the compositions can be prepared according to techniques well-known in the art of pharmaceutical formulation. The compositions can contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents. As immediate release tablets, the compositions can contain microcrystalline cellulose, starch, magnesium stearate and lactose or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
For administration by inhalation or aerosol, the compositions can be prepared according to techniques well-known in the art of pharmaceutical formulation. The compositions can be prepared as solutions in saline, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons or other solubilizing or dispersing agents known in the art.
For administration as injectable solutions or suspensions, the compositions can be formulated according to techniques well-known in the art, using suitable dispersing or wetting and suspending agents, such as sterile oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
For rectal administration as suppositories, the compositions can be prepared by mixing with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 12 Preferred administration routes include orally, parenterally, as well as intravenous, intramuscular or subcutaneous routes.
More preferably, the compounds of the present invention are administered parenterally, intravenously or intraperitoneally, by infusion or injection. In one embodiment of the invention, the compounds may be administered directly to a tumor by tumor injection; or by systemic delivery by intravenous injection.
Solutions or suspensions of the compounds can be prepared in water, isotonic saline (PBS) and optionally mixed with a nontoxic surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene, glycols, DNA, vegetable oils, triacetin and mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage form suitable for injection or infusion use can include sterile, aqueous solutions or dispersions or sterile powders comprising an active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol such as glycerol, propylene glycol, or liquid polyethylene glycols and the like, vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size, in the case of dispersion, or by the use of nontoxic surfactants. The prevention of the action of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be desirable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the inclusion in the composition of agents delaying absorption-for example, aluminum monosterate hydrogels and gelatin.
Sterile injectable solutions are prepared by incorporating the conjugates in the required amount in the appropriate solvent with various other ingredients as enumerated above and, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying techniques, which SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/1 4758 13 yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
Conjugation to a Targeting Moiety The compound of the invention can be targeted for specific delivery to the cells to be treated by conjugation of the compounds to a targeting moiety. Targeting moiety useful for conjugation to the compounds of the invention include antibodies, cytokines, and receptor ligands expressed on the cells to be treated.
The term "conjugate" means a complex formed with two or more compounds.
The phrase "targeting moiety" means a compound which serves to deliver the compound of the invention to a specific site for the desired activity. Targeting moieties include, for example, molecules which specifically bind molecules present on a cell surface. Such targeting moieties useful in the invention include anti-cell surface antigen antibodies. Cytokines, including interleukins, factors such as epidermal growth factor (EGF), and the like, are also specific targeting moieties known to bind cells expressing high levels of their receptors.
Particularly useful targeting moieties for targeting the compounds of the invention to cells for therapeutic activity include those ligands that bind antigens or receptors present on the tumor cells to be treated. For example, antigens present on B-lineage cancer cells, such as CD 19, can be targeted with anti-CD 19 antibodies such as B43. Antibody fragments, including single chain fragments, can also be used. IL4 can also be used to target B-cells. Cancer cells expressing EGF or IGF receptors can be targeted with the binding ligand. Other such ligand-receptor binding pairs are known in the scientific literature for specific cancers. Methods for producing conjugates of the compounds of the invention and the targeting moieties are known.
Useful Dose When used in vivo to kill tumor cells, the administered dose is that effective to have the desired effect, such as sufficient to reduce or eliminate tumors.
Appropriate amounts can be determined by those skilled in the art, extrapolating using known methods and relationships, from the in vitro data provided in the Examples.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/IJS99/1 4758 14 In general, the dose of the novel alkyl ketone compounds effective to achieve tumor cell apoptosis, reduction in tumors, and increased survival time, is 1-100 mg/kg body weight/dose for a direct targeted administration.
The effective dose to be administered will vary with conditions specific to each patient. In general, factors such as the disease burden, tumor location (exposed or remote), host age, metabolism, sickness, prior exposure to drugs, and the like contribute to the expected effectiveness of a drug. One skilled in the art will use standard procedures and patient analysis to calculate the appropriate dose, extrapolating from the data provided in the Examples.
In general, a dose which delivers about 1-100 mg/kg body weight is expected to be effective, although more or less may be useful.
In addition, the compositions of the invention may be administered in combination with other anti-tumor therapies. In such combination therapy, the administered dose of the alkyl ketone compounds may be less than for single drug therapy.
EXAMPLES
The invention may be further clarified by reference to the following Examples, which serve to exemplify some of the embodiments, and not to limit the invention in any way.
Example 1 Synthetic procedure for Alkyl Ketones The methods used to synthesize the alkyl ketone compounds beginning from readily available starting materials and ending with the desired compounds are described below.
The compounds contained within Table 1, Table 2, Table 3, and Table 6 were synthesized according to Schemes 1, 2, 3, and 4 illustrated below. In each scheme, a single compound is exemplified and used as a model to generally describe the synthesis. The specific synthesis of the other compounds is then discussed in detail.
The pathway used to synthesize the remaining compounds contained within Tables 3 and 6 and the compounds in Tables 4 and 5 are also described in detail below.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 All chemicals were purchased from Aldrich Chemical Company (Milwaukee, Wisconsin) and used directly for synthesis without further purification. Anhydrous tetrahydrofuran was dried over sodium and distilled immediately prior to use.
Column chromatography was performed using 230-400 mesh silica gel obtained from the Merck Company, with eluant as noted in the experimental procedure.
COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 1 The compounds (3a-e and 4a-e in Table 1; 3f, 4f, 3g, and 4g in Table 2) were prepared by the pathway exemplified in Scheme 1 for N-Ac-S-farnesyl-Cys chloromethyl ketone (HI-368) (4a).
Scheme 1 Farnesyl ,SH -S i) NMM, i-BuOCOCI Farnesyl-Br THF, -15 OC AcsH Ac N H a- H 0 NH 3 MeOH H ii) CH 2
N
2 Et 2 0, 0 C O O 1 2a Farnesyl Farnesyl
HCI
AcH EtOAc AcN Cl H 8
O"C
0 0 3a 4a General description of the synthetic pathway illustrated in Scheme 1 The first step of scheme 1 was isoprenylation of the thiol group of N-Ac- Cys-OH by reaction of the appropriate isoprenyl bromide in a 4 M solution of ammonia in methanol according to the method of Brown and co-workers. This step was carried out in the presence of ethyl acetate when N-Ac-Cys-OH was dodecylated in order to solvate the bromododecane. In the second step, the Salkylated acid (2a) was activated as the mixed anhydride derivative using isobutylchloroformate and converted to the diazomethyl ketone (3a) by treatment with diazomethane. In the last step, the diazomethane was converted to the chloromethyl ketone (4a) with HC1 in ethyl acetate at 0 °C for 10 minutes.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 16 The chloromethyl compounds in Tables 1 and 2, 4a-4g, were made from the analogous diazomethyl compounds, 3a-3g, by replacement of the diazomethyl group with a chloromethyl group. The specific synthesis of each two member analogous group will therefore be considered together.
Specific methods used to synthesize the analogous pain of diazomethyl compounds using Scheme 1 1. N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone (HI-367)(3a) and N-Ac-S-trans-trans-farnesyl-Cys chloromethyl ketone (HI-368)(4a) Trans-trans -farnesyl bromide (1.57 g, 1.49 mL, 5.5 mmol) was added to N-Ac-Cys-OH (0.82 g, 5 mmol) in 4 M ammonia in methanol (35 mL) at 0 OC.
The reaction was stirred at 0 °C for 3 h then at room temperature for 1 h. The solvent was removed under reduced pressure and the residue partitioned between 1butanol and water. The butanol layer was dried (MgSO 4 and the solvent removed under reduced pressure. The residue was redissolved in methanol and washed with hexane. The methanol was then removed under reduced pressure to give N-Ac-Strans-trans-famesyl-Cys-OH (2a).
The N-Ac-S-trans-trans-faresyl-Cys-OH (2a) (1.84 g, 5 mmol) produced in the previous step was dissolved in dry THF (30 mL) and cooled to 15 OC. 4-methyl morpholine (0.51 g, 0.55 mL, 5 mmol) and iso-butyl chloroformate (0.68 g, 0.65 mL, 5 mmol) were added to the solution. The mixture was stirred at -15 °C for 5 minutes before being filtered by gravity into a solution of diazomethane in ethanolic ether (11 mmol, 30 mL) cooled in an ice bath. The resulting solution was stirred in ice for 3 h. Excess diazomethane was purged with nitrogen gas and the reaction mixture was washed with 5% sodium bicarbonate solution and water, dried over MgSO 4 and then the solvent was removed under reduced pressure. The product was purified by chromatography on silica gel ethyl acetate in hexane) to give N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone (3a).
A solution of HC1 in ethyl acetate (1 M, 2 mL, 2 mmol) was added to a solution of the previously synthesized N-Ac-S-trans-trans-faresyl-Cys diazomethyl ketone (3a) (1.57 g, I mmol) in ethyl acetate (10 mL) cooled in an ice SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCTJUS99/I 4758 17 bath. The reaction mixture was stirred at 0 'C for 5 to 10 min until the starting material was consumed by TLC. The solvent was then removed under reduced pressure and the residue purified by chromatography on silica gel (1:3 ethyl acetate:hexane) to give N-Ac-S-trans-trans-farnesyl-Cys chioromethyl ketone (4a).
2. N-Ac-S-trans-geranyl-Cys diazometbyl ketone (14I-122)(3c) and N-Ac-S-trans-geranyl-Cys chioromethyl ketone (HI-127)(4c) N-Ac-S-trans-geranyl-Cys-OH (2c) was prepared as described above for N-Ac-S -trans- trans-fanesyl-Cys-OH (2a) except that trans-geranyl bromide was used instead of famnesyl bromide.
N-Ac-S-trans-geranyl-Cys diazomethyl ketone (HI 122) (3c) was prepared as described above for N-Ac-S-trans- trans-farnesyl-Cys diazomethyl ketone (3a) except that N-Ac-S-trans-geranyl-Cys-OH (2c) (2.99 g, 10 mmol) was used instead of N-Ac-S-trans- trans-farnesyl-Cys-OH The crude material produced was purified by chromatography on silica gel (0-67% ethyl acetate in hexane) to give N-Ac-S-trans-geranyl-Cys diazomethyl ketone (HI 122) (3c).
N-Ac-S-trans-geranyl-Cys chioromethyl ketone (HI1127) (4c) was prepared as described above for N-Ac-S-trans- trans-f amesyl-Cys chioromethyl ketone (4a) except that N-Ac-S-trans-geranyl-Cys diazomethyl ketone (3c) (0.10 g, 0.3 mmol) was used instead of N-Ac-S-trans-trans-f amesyl-Cys diazomethyl ketone (3 The crude material produced was purified by chromatography on silica gel (0-40% ethyl acetate in hexane) to give N-Ac-S-trans-gerany-Cys chioromethyl ketone (HI 127) (4c).
3. N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (HI-123)(3d) and N-Ac-S-(3-methyl-2-butenyl)-Cys chioromethyl ketone (HI-128)(4d) N-Ac-S-(3-methyl-2-butenyl)-Cys-OH (2d) was prepared as described above for N-Ac-S-trans-trans-fanesyl-Cys-OH (2a) except that 4-bromo-2 methyl-2-butene was used instead of farnesyl bromide.
N-Ac-S-(3-methyl-2-butenyl)-Cys diazomnethyl ketone (3d) was prepared as described above for N-Ac-S-trans- trans-fanesyl-Cys diazomethyl ketone (3 a) except that N-Ac-S-(3'-methyl-2-butenyl)-Cys5OH (2d) (0.69 g, 3 mmol) was SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 18 used instead of N-Ac-S-trans-trans-farnesyl-Cys-OH The crude material was purified by chromatography on silica gel methanol in methylene chloride) to give N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d).
N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (4d) was prepared as described above for N-Ac-S-trans-trans-farnesyl-Cys chloromethyl ketone (4a) except that N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d) (0.30 g, 1.2 mmol) was used instead of N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone The crude product was purified by chromatography on silica gel (0-50% ethyl acetate in hexane) to give N-Ac-S-(3-methyl-2butenyl)-Cys chioromethyl ketone (4d).
4. N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348) (3e) and N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131) (4e) N-Ac-Cys-OH (1.62 g, 9.9 mmol) and bromododecane (2.5 g, 10 mmol) were dissolved in a mixture of ethyl acetate (30 mL) and methanol (20 mL). A solution of NH 3 (4.2 M, 100 mL) in methanol was added at 0 OC and the reaction mixture was allowed to stir overnight at room temperature. The solvent was then removed under reduced pressure and the residue was partitioned between ethyl acetate and 1 M HC. The organic layer was dried over MgSO 4 and the solvent removed under reduced pressure to give N-Ac-S-dodecyl-Cys-OH (2e).
N-Ac-S-dodecyl-Cys diazomethyl ketone (3e) was prepared as described above for N-Ac-S-trans- trans-farnesyl-Cys diazomethyl ketone (3a) except that N-Ac-S-dodecyl-Cys-OH (2e) (0.96 g, 2.9 mmol) was used instead of N-Ac-Strans- trans-farnesyl-Cys-OH The crude product was purified by chromatography on silica gel (1:3 ethyl acetate/hexane) to give N-Ac-S-dodecyl- Cys diazomethyl ketone (3e).
N-Ac-S-dodecyl-Cys chloromethyl ketone (4e) was prepared as described above for N-Ac-S-farnesyl-Cys chloromethyl ketone (4a) except that N-Ac-Sdodecyl-Cys diazomethyl ketone (3e) (0.19 g, 0.5 mmol) was used instead of N- Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone N-Ac-S-dodecyl-Cys chloromethyl ketone (4e) was obtained after removal of solvent.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCTIUS99/1 4758 19 N-Boc-S-farnesyl-Cys diazomiethyl ketone (HI-82) (3b) and N-Boc-S-farnesyl-Cys chioromethyl ketone (HI-124) (4b) These compounds were prepared using published literature procedures starting from L-cysteine.
6. S-trans-trans-Farnesyl-mercaptoethyl diazomiethyl ketone (HI 83) (31) and S-trans-trans-Farnesyl-2-mercaptoethyl chioromethyl ketone (HI 125) (4Q) 3-(S-trans- trans-Farnesyl)-mercaptopropionic acid (21) was prepared as described above for N-Ac-S-trans-trans-famesyl-Cys-OH (2a) except that 3mercaptopropionic acid was used instead of N-Ac-Cys-OH S-trans- trans-Farnesyl-mercaptoethyl diazomethyl ketone (31) was prepared as described above for N-Ac-S-trans- trans-farnesyl-Cys diazomethyl ketone (3a) except that 3-(S-trans-trans-Fanesyl)-mercaptopropionic acid (2f) was used instead of N-Ac-S-trans- trans-farnesyl-Cys-OH The crude material was purified by chromatography on silica gel MeOH in CHC1 3 to give S-trans-trans-Farnesyl-mercaptoethyl diazomethyl ketone (31).
S-trans- trans-Farnesyl-2-mercaptoethyl chioromethyl ketone (HI 125) (4f) was prepared as described above for N-Ac-S--trans- trans-farnesyl-Cys chioromethyl ketone (4a) except that S-trans-trans-Fanesyl-mercaptoethyl diazomethyl ketone (31) (0.52 g, 1.6 mmol) was used instead of N-Ac-S -transtrans-farnesyl-Cys diazomethyl ketone The crude product was purified by chromatography on silica gel 10% ether in hexane) to give S-trans-trans- Farnesyl-2-mercapto ethyl chioromethyl ketone (HII 125) (41).
7. S-trans-trans-Farnesyl-mereaptomethyl diazomethyl ketone (HI 84) (3g) and S-trans-trans-Farnesyl-mereaptomethyl chioromethyl ketone (HI 126) (4g) S-trans- trans-Farnesyl-mercaptoacetic acid (2g) was prepared as described above for N-Ac-S-trans- trans-farnesyl-Cys-OH (2a) except that mercaptoacetic acid was used instead of N-Ac-Cys-OH S-trans--trans-Fanesyl-mercaptomethyl diazomethyl ketone (3g) was prepared as described above for N-Ac-S-trans-trans-fanesyl-Cys diazomethyl ketone (3a) except that S-trans-trans-Farnesyl-mercaptoacetic acid (2g) (0.71 g, SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCTIUS99/1 4758 2.4 mmol) was used instead of N-Ac-S-trans-trans-fanesyl-Cys-OH The crude material was purified by chromatography on silica gel (0-100% CHC 3 in hexane) to give S-trans-trans-Farnesyl-m ercaptom ethyl diazomethyl ketone (3g).
S-trans-trans-Farnesyl-mercaptomethyl chioromethyl ketone (4g) was prepared as described above for N-Ac-S-trans- trans-famesyl-Cys chioromethyl ketone (4a) except that S-trans- trans-Farnesyl-mercaptomethyl diazomethyl ketone (3g) (0.58 g, 1.8 mmol) was used instead of N-Ac-S-trans-trans-farnesyl- Cys diazomethyl ketone The crude product was purified by chromatography on silica gel 10% ether in hexane) to give S-trans-trans-Farnesylmercaptomethyl chioromethyl ketone (4g).
COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 2 The synthesis of compounds 8 and 9 in Table 1 were prepared by the pathway exemplified in Scheme 2.
Scheme 2 Dodecyl Dodecyl I
I
~.HDodecyl&r i) Boo2O, EtOAc H2 (OCF" 3 N~b MeOH, EtOAc H 2 N I%~Cbt ii) NaQH, MeQH ocN~to 0 0 0 6 7 I) MMi-BOCCIDodecyl Dodecyl i MB CC I I THF, -15-C SHCI ii) C"-k2, Et 2 O, O'C Bo0,JN EtOAc HCI H 2 NWf' I1 iii) HCI, EtOAc, 0 -C H 00 8 9 General description of the synthetic pathway illustrated in Scheme 2 The first step in scheme 2 was the dodecylation of cysteine methyl ester in a mixture of ethyl acetate and methanol. This was followed by Boc-protection, ester hydrolysis and conversion in turn to the chioromethyl ketone S-Dodecyl-Cys chloromethyl ketone hydrochloride was prepared from N-Boc-S-dodecylVCys SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 21 chloromethyl ketone by simply deprotecting the Boc group in a saturated solution of HCl in ethyl acetate.
Specific methods used to synthesize compounds using Scheme 2 8. N-Boc-S-dodecyl-Cys chloromethyl ketone (HI-129) and S-Dodecyl-Cys chloromethyl ketone hydrochloride (HI-252) (9) Ethyl acetate (30 mL) was added to a mixture of Cys-OCH 3 hydrochloride (1.71 g, 10 mmol) and bromododecane (2.5 g, 10 mmol) followed by addition of a solution of NH 3 (6.4 M) in methanol. The resulting cloudy suspension was allowed to stir overnight at room temperature and then the insoluble material was filtered off.
The solution was concentrated and ethyl acetate (100 mL) was added. The solution was subsequently washed with water (3 x 40 mL) and dried over Na 2
SO
4 to obtain S-Dodecyl-Cys-OCH 3 Di-tert-butyl dicarbonate (1.7 mL, 7.4 mmol) was added to a solution of the previously synthesized S-dodecyl-Cys-OCH 3 (2.11 g, 7 mmol) in ethyl acetate at 0 °C The reaction mixture was allowed to stir for 4 h at room temperature. N- Boc-S-dodecyl-Cys-OCH 3 was obtained after removal of solvent.
A solution of NaOH (3 M, 3.6 mL, 10.8 mmol) was added to a solution of N-Boc-S-dodecyl-Cys-OCH 3 (3.42 g, 8.5 mmol) in methanol (80 mL) at 0 °C.
The reaction mixture was allowed to stir overnight at room temperature and then the solvent was removed under reduced pressure. Water (50 mL) was added to the residue and the aqueous solution, whose pH value was adjusted to 5, was washed with hexane (2 x 30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined ethyl acetate fractions were dried over anhydrous Na 2
SO
4 and the solvent removed under reduced pressure to give N-Boc-S-dodecyl-Cys-OH N-Boc-S-dodecyl-Cys diazomethyl ketone was prepared as described above for N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone (3a) except that N-Boc-S-dodecyl-Cys-OH (0.89 g, 2.3 mmol) was used instead of N-Ac-S- SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 22 trans-trans-farnesyl-Cys-OH The crude product was purified by chromatography on silica gel (1:2 ethyl acetate/hexane) to give N-Boc-S-dodecyl- Cys diazomethyl ketone.
N-Boc-S-dodecyl-Cys chloromethyl ketone was prepared as described above for N-Ac-S-trans- trans-faresyl-Cys chloromethyl ketone (4a) except that N-Boc-S-dodecyl-Cys diazomethyl ketone (0.56 g, 1.4 mmol) was used instead of N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone N-Boc-S-dodecyl- Cys chloromethyl ketone was obtained upon removal of solvent.
The N-Boc-protected chloromethyl ketone (0.21 g, 0.5 mmol) was dissolved in ethyl acetate (20 mL) and cooled in an ice bath. It was then saturated with dry HCI gas and the solution was stirred at room temperature until the starting material had disappeared by TLC (approx. 2 The solvent was removed under reduced pressure and the product, S-Dodecyl-Cys chloromethyl ketone hydrochloride was obtained after recrystallization from ether.
COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 3 The compounds 12 and 13 in Table 1 were prepared by the pathway exemplified in Scheme 3.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCT/US99/1 4758 23 Scheme 3 Famesyl Famesyi SH Farnesyl-Br S i) Boc-Gly-OH, EDO, HOBt 0 -S
H
2 NZ'e fA3 NH 3 MeOH H 2 NJyOCH3 ii) NaOH, MeOH BOC H 0 0 0 10 11 i) NMM, i-BuOCOCI I~msI aey THF, 15 -C H 0 S HC1, EtOAc, 0 C 0 'A ii) CH9J 2 Et 2 O, OOC Boe'-' "N 2 Ba'N NI 00 12 13 General description of the synthetic pathway illustrated in Scheme 3 The first step in scheme 3 was the farnesylation of cysteine methyl ester according to the method of Brown et al. The farnesylated cysteine methyl ester was then coupled with N-Boc-Gly-OH using EDCIHOBt. The ester was hydrolyzed to the acid (11) and the chioromethyl ketone prepared via the diazomethyl ketone (12).
Specific methods used to synthesize compounds using Scheme 3 9. N-Boc-Gly-S-trans-trans-farnesyl-Cys diazomethyl ketone (111401) (12) and N-Boc-Gly-S-trans-trans-farnesyl-Cys chioromethyl ketone (HI-130) (13) A solution of ammonia (3.4 M, 80 mL) in methanol was added to a mixture of Cys-OCH 3 hydrochloride (1.72 g, 10 mmol) and trans- trans-fanesyl bromide (2.85 g, 10 mmol) in methanol (3 0 mL) at 0 The reaction mixture was allowed to stir overnight at room temperature and then the solvent was removed under reduced pressure. The remaining residue was dissolved in ethyl acetate (100 mL) which had been washed with HCl (0.3 water, NaHCO 3 and dried over Na 2
SO
4 The solvent was then removed under reduced pressure to give S-transtrans-Famesyl-Cys-OCH3 DMF (30 mL) was added to a mixture of N-Boc-Gly-OH (1.3 g, 7.5 mmol), S-trans-trans-Fanesyl-Cys-OCH3 (10) (1.28 g, 7.5 mmol) and HOBt (0.6 g, 4.4 SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 24 mmol). The solution was cooled to 0 oC before the addition of EDC (1.52 g, 8.2 mmol) and the reaction mixture was stirred overnight at room temperature. The solvent was then removed under reduced pressure. The resulting residue was dissolved in ethyl acetate (60 mL) which had been washed with HC1 (0.2 water, NaHCO 3 and dried over Na 2
SO
4 Removal of the solvent under reduced pressure gave a yellow oil that was purified via chromatography on silica gel (1:1 ethyl acetate/hexane) to give pure N-Boc-Gly-S-trans-trans-farnesyl-Cys-OCH3 N-Boc-Gly-S-trans-trans-faresyl-Cys-OCH3 (1.25 g, 2.52 mmol) was dissolved in methanol (70 mL) and then a solution of NaOH (3 M, 2.5 mL, 7.56 mmol) at 0 °C was added. The solution was stirred overnight at the same temperature. The solvent was then removed and the residue was dissolved in water mL) that was subsequently acidified to pH 5. The aqueous solution was extracted with chloroform, the combined organic fractions were dried over anhydrous Na 2
SO
4 and the solvent was removed under reduced pressure to give N- Boc-Gly-S-trans- trans-farnesyl Cys-OH (11).
N-Boc-Gly-S-trans- trans-farnesyl-Cys diazomethyl ketone (12) was prepared as described above for N-Ac-S-trans- trans-famesyl-Cys chloromethyl ketone (4a) except that N-Boc-Gly-S-trans-trans-faresyl-Cys-OH (11) (0.39 g, 0.8 mmol) was used instead of N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone The crude material was purified by chromatography on silica gel (1:3 ethyl acetate/hexane) to give N-Boc-Gly-S-trans-trans-farnesyl-Cys diazomethyl ketone (12).
N-Boc-Gly-S-trans-trans-faresyl-Cys chloromethyl ketone (13) was prepared as described above for N-Ac-S-trans- trans-famesyl-Cys chloromethyl ketone (4a) except that N-Boc-Gly-S-trans-trans-farnesyl-Cys diazomethyl ketone (0.21 g, 0.41 mmol) was used instead of N-Ac-S-trans- trans-farnesyl-Cys diazomethyl ketone N-Boc-Gly-S-trans-trans-farnesyl-Cys chloromethyl ketone (13) was obtained upon removal of solvent.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 4 The compounds 4h-4y in Table 3 and the compounds in Table 6 were prepared by the pathway exemplified in Scheme 4.
Scheme 4 R R SH i) NMM, i-BuOCOCI S AN H R-Br, NH 3 P THF, -78°C Acs H Ac---N H Acs H Ac MeOH, EtOAc H ii) CH 2
N
2 Et 2 0 N O O iii) HCI, EtOAc, o0C O 1 2h-y 4h-y Synthesis of the straight chain alkyl ketone derivatives (Tables 3 and 6) The straight chain alkyl ketone derivatives (4h-y) were synthesized by a modification of the standard literature procedure. Previously, the standard conditions for making diazomethyl ketones were used, but a closer study of the dodecyl derivative, N-Ac-S-dodecyl-Cys chloromethyl ketone showed significant formation of the methyl ester as a side-product. Presumably, the mixed anhydride intermediate either could not completely form or was hydrolyzed back to the acid before the diazomethane could react with it. Conducting the mixed anhydride formation at -78 OC increased the stability and longevity of the mixed anhydride and improved yield. Adding diazomethane directly to the solution at 78 °C without filtration led to over a three-fold improvement in yield from 15 to for the dodecyl derivative, N-Ac-S-dodecyl-Cys chloromethyl ketone (4e), and gave a satisfactory yield of product for the majority of cysteine derivatives reported herein.
Specific methods used to synthesize the compounds of Table 3 and Table 6 The appropriate 1-bromoalkane (11 mmol) was added to a solution of N- Ac-Cys-OH (1.63 g, 10 mmol) in methanol (15 mL) and ethyl acetate (15 mL) that had been cooled in an ice bath. This was followed by the addition of a solution of ammonia in methanol (4M, 50 mL). The resulting solution was allowed to slowly warm to room temperature and was stirred overnight. The solvent was then removed under reduced pressure and the residue partitioned between ethyl acetate and 1 M SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 26 HC1. The layers were separated and the organic layer was dried over anhydrous MgSO 4 The solvent was removed under reduced pressure to give the desired N- Ac-S-alkyl-cysteine compound. An analytical sample of this could be obtained by recrystallization from ethyl acetate/hexane but was otherwise of sufficient purity to be used in further reactions.
NMM (0.20 g, 0.22 mL, 2 mmol) and isobutyl chloroformate (0.27 g, 0.26 mL, 2 mmol) was added to the desired N-Ac-S-alkyl-cysteine (2 mmol) in anhydrous THF (20 mL) that had been cooled to -78 The solution was then stirred at -78 "C for 20 min. A solution of diazomethane in ethanolic ether (10 mL) was carefully added and the solution allowed to slowly warm to room temperature.
Further portions of diazomethane solution were added until a yellow color persisted.
The solution was diluted with ether, washed with water and sodium bicarbonate solution and then dried over anhydrous MgSO 4 The solvent was removed under reduced pressure to yield the crude diazomethyl ketone compound.
The diazomethyl ketone was dissolved in ethyl acetate (20 mL) and cooled in an ice bath. A solution of HC1 in ethyl acetate (2M, 2 mL) was added and the solution stirred in ice for 5 min until no more diazomethyl ketone could be observed by TLC. The solvent was removed under reduced pressure and the residue purified by chromatography on silica gel (ethyl acetate/hexane) to give the pure chloromethyl ketone compounds in Table 3 and Table 6.
11. Synthesis of the alkyl ketone compounds in Table 4 Synthesis of the compounds having variable R' groups shown in Table 4 was either by the method described above for HI-131, 348,and 208 or as follows. The bromomethyl ketone (HI-488) was synthesised from the diazomethyl ketone using HBr in a similar fashion to the chloromethyl ketone. The benzoyloxymethyl ketone (HI-508) was made starting from either the bromomethyl ketone or the chloromethyl ketone by displacement of the halogen with benzoic acid in the presence of potassium fluoride in DMF. The aldehyde (HI-274) was made from the acid (HI- 208, 2e) via formation of the Weinreb amide (HI-267) by activation of the acid as its' mixed anhydride followed by coupling with N,O-dimethylhydroxylamine. The aldehyde was then synthesized by reduction of the Weinreb amide using LiAlH 4 The thiomethyl ketones (HI-269, 302, 399, 365 273) were made by displacement SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 27 of the halogen of the bromo or chloromethyl ketones with the appropriate thiol in the presence of potassium carbonate in DMF.
12. Synthesis of the alkyl ketone compounds in Table The compounds varying the R 4 substituent (Table 5) were made either as noted above for HI-252, 131, and 129 or as follows. The majority of these compounds were made by reacting the appropriate acyl chloride or anhydride with the free amine compound (HI-252) in the presence of triethylamine. The dimethylaminobenzoyl derivative (HI-268) required activation of dimethylaminobenzoic acid as its mixed anhydride prior to reaction with the free amine. The serine derivative (HI-266) was synthesized by reaction of Boc-Ser-OH with sodium hydride and 1-bromododecane in DMF to give the N-Boc-Ododecyl-Ser-OH and then with isobutylchloroformate/diazomethane and HC1 in ethyl acetate at 0 OC as in the chemistry noted above. The acetyl serine derivative (HI-489) was synthesized from HI-266 by removal of the Boc group in saturated HC1 in ethyl acetate followed by acetylation using acetic anhydride in dichloromethane in the presence of triethylamine.
Example 2 Characterization of synthesized compounds NMR spectra were recorded using a 300 MHz Varian instrument and the chemical shifts reported are in ppm based on tetramethylsilane as the internal standard. Chemical shifts for 3 C NMR are referenced to the chloroform peak at 77.0 ppm. Melting points were done using a Fisher-Jones apparatus and are uncorrected. Fourier Transform Infra-red spectra were recorded on a FT-Nicolet model Protege 460 instrument. GC/MS analysis was done using a Hewlett-Packard GC/MS model 6890 with an HP5973 electron impact mass spectrometer. In addition, a Hewlett-Packard Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) spectrometer model G2030A was used with cyano hydroxy benzoic acid as the matrix. Data are shown below.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 28 N-Ac-S-trans-trans-farnesyl-Cys-OH (2a) Yellow oil. Yield 99%, 1.83 grams. 'H NMR (DMSO-d 6 6 1.54 6H), 1.61 3H), 1.62 3H), 1.84 3H), 1.97 8H), 2.60 (dd, J 8.5, 13.7 Hz, 1H), 2.79 (dd, J= 5.0, 13.7 Hz, 1H), 3.13 2H), 4.35 1H), 5.05 2H), 5.14 J= 7.8 Hz, 1H), 8.22 J= 8.2 Hz, 1H); C NMR (CDCl 3 8 172.5, 169.5, 138.7, 134.8, 130.9, 124.3, 123.8, 120.4, 52.1, 48.8, 32.2, 29.0, 26.4, 26.1, 25.8, 22.6, 17.8, 16.1, 16.0; IR (KBr) 3334, 2966, 2922, 2854, 1732, 1659, 1543, 1441, 1377, 1219 cm N-Ac-S-trans-geranyl-Cys-OH (2c) Clear oil. Yield 97%, 2.92 g. 'H NMR (CDCl 3 6 1.60 3H), 1.65 3H), 1.68 3H), 2.07 4H), 2.10 3H), 2.95 (ABX, J= 3.6, 5.7, 13.2 Hz, 2H), 3.18 J= 6.9 Hz, 2H), 4.72 1H), 5.07 1H), 5.20 J= 7.9 Hz, 1H), 6.72 (br, 1H), 9.95 (br, 1H); 3 C NMR (CDC1 3 6 177.1, 139.9, 131.6, 123.7, 119.4, 52.6, 39.7, 33.0, 30.1, 29.8, 26.5, 25.8, 23.0, 20.9, 17.8, 16.2; IR (KBr) 3307, 2968, 2857, 2611, 1716, 1646, 1550, 1417, 1377, 1241 cm'; MS (MALDI-TOF) 323 (M H Na).
N-Ac-S-(3-methyl-2-butenyl)-Cys-OH (2d) Clear viscous oil. Yield 83%, 0.96 g. 'H NMR (CDC13) 8 1.66 3H), 1.73 3H), 2.07 3H), 2.95 (ABX, J= 4.6, 6.2, 13.9 Hz, 2H), 3.17 J= 7.7 Hz, 2H), 4.65 1H), 5.20 J= 7.9 Hz, 1H), 7.28 (br, 1H), 8.25 (br, 1H); 13C NMR (CDC1 3 6 174.1, 171.2, 136.1, 119.7, 52.7, 33.1, 30.1, 25.9, 25.8, 22.9, 17.8; IR (KBr) 3271, 3078, 2966, 2930, 2874, 1722, 1651, 1615, 1557, 1427, 1377, 1299, 1213, 1107, 1031 cm N-Ac-S-dodecyl-Cys-OH (2e) White solid. Yield 98%, 3.23 g. m.p. 82- 84 OC. 'H NMR (CDC1 3 6 0.88 J= 6.6 Hz, 3H), 1.26 20H), 1.57 2H), 2.09 3H), 2.55 J 7.4 Hz, 2H), 3.03 2H), 4.75 1H), 6.40 J= 7.1 Hz, 1H); C NMR (CDC13) 6 168.3, 47.3, 28.8, 28.1, 27.3, 25.0, 24.9, 24.8, 24.6, 24.2, 18.4, 18.1, 9.6; IR (KBr) 3334, 2922, 2850, 1703, 1622, 1562, 1470, 1416, 1377, 1315, 1257, 1244 MS (MALDI-TOF) 332.7 (M 1).
3-(S-trans-trans-Farnesyl)-mercaptopropionic acid (2f) Clear oil.
Yield 100%, 1.54 g. 'H NMR (CDC13) 6 1.60 6H), 1.66 3H), 1.68 3H), 2.03 8H), 2.60 J= 6.8 Hz, 2H), 2.72 J= 6.8 Hz, 2H), 3.17 J= 7.7 Hz, 2H), 5.09 2H), 5.22 J= 7.3 Hz, 1H), 8.77 (br, 1H); 'C NMR (CDC1 3 6 162.9, 139.0, 135.2, 131.2, 124.2, 123.7, 120.0, 60.4, 39.75, 39.65, 36.8, 35.3, 31.7, 29.4, 26.8, 26.5, 26.1, 25.8, 17.8, 16.2, 16.1; IR (KBr) 3179, 2969, 2920, 2855, 1710, 1595, 1436, 1381, 1307 cm'.
S-trans-trans-Farnesyl-mercaptoacetic acid (2g) Clear oil. Yield 97%, 1.43 g. 'H NMR (CDC1 3 8 1.60 6H), 1.66 3H), 1.68 3H), 2.03 8H), 3.19 2H), 3.30 J= 7.7 Hz, 2H), 5.09 2H), 5.21 1H), 8.95 (br, 1H); 1 3
C
NMR (CDC13) 176.5, 140.7, 135.3, 131.2, 124.2, 123.5, 118.9, 39.7, 39.6, 32.0, 30.0, 26.8, 26.4, 25.8, 17.8, 16.12, 16.09; IR (KBr) 3323, 2959, 2925, 2875, 1705, 1605, 1436, 1381, 1227, 1073, 1033 cm SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 29 N-Ac-S-trans-trans-farnesyl-Cys diazomethyl ketone (HI 367) (3a) Yellow oil. Yield 51%, 1 g. 'H NMR (CDCl 3 6 1.60 6H), 1.67 3H), 1.68 (s, 3H), 2.03 8H), 2.05 3H), 2.82 (ABX, J 6.3, 6.6, 14.0 Hz, 2H), 3.20 (m, 2H), 4.64 1H), 5.09 J= 6.9 Hz, 2H), 5.22 J= 7.7 Hz, 1H), 5.58 1H), 6.51 J= 7.7 Hz, 1H); 3 C NMR (CDC13) 6 191.8, 169.7, 139.9, 135.3, 131.2, 124.2, 123.6, 119.5, 60.3, 55.2, 54.9, 39.65, 39.55, 33.1, 30.1, 26.7, 26.3, 25.7, 23.1, 17.7, 16.1, 16.0; IR (KBr) 3290, 3057, 2966, 2920, 2854, 2108, 1651, 1533, 1441, 1375 GC/MS 363 (M N 2 N-Ac-S-trans-geranyl-Cys diazomethyl ketone (HI 122) (3c) Yellow oil. Yield 45%, 1.45 g. 'H NMR (CDC1 3 6 1.60 3H), 1.67 3H), 1.68 3H), 2.05 7H), 2.82 (ABX, J 6.0, 6.3, 13.8 Hz, 2H), 3.20 2H), 4.64 1H), 5.08 2H), 5.22 J 7.8 Hz, 1H), 5.59 1H), 6.56 J= 7.2 Hz, 1H); 3
C
NMR (CDC1 3 6 191.8, 169.7, 139.8, 131.6, 123.7, 119.5, 65.8, 55.3, 55.0, 39.6, 33.1,30.2,29.7,26.5,25.8,23.2, 17.8, 16.2; GC/MS 295 (M N 2 IR(KBr) 3300, 3061, 2965, 2924, 2856, 2107, 1732, 1651, 1538, 1455, 1373, 1260, 1111 MS (MALDI-TOF) 296.5 (M H N 2 N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (HI 123) (3d) Yellow oil. Yield 50%, 0.38 g. 'H NMR (CDC13) 8 1.68 3H), 1.75 3H), 2.05 3H), 2.82 (ABX, J= 6.0, 6.3, 13.5 Hz, 2H), 3.18 2H), 4.64 1H), 5.21 (m, 1H), 5.59 1H), 6.58 J= 7.5 Hz, 1H); "C NMR (CDC1 3 191.7, 169.6, 136.1, 119.7, 55.3, 54.9, 52.7, 52.6, 51.8, 37.7, 33.2, 30.3, 30.1, 25.7, 25.6, 23.1, 19.1, 17.8; GC/MS 227 (M N 2 IR (KBr) 3296, 3062, 2970, 2928, 2108, 1745, 1667, 1548, 1441, 1373, 1145, 1039 MS (MALDI-TOF) 278.6 (M Na), 256.3 (M 250.4 (M Na N 2 228.3 (M H N 2 N-Ac-S-dodecyl-Cys diazomethyl ketone (HI 348) (3e) Off-white solid.
Yield 15%, 0.16 g. m.p. 45-48 OC. 'H NMR (CDCl 3 8 0.88 J= 6.7 Hz, 3H), 1.25 18H), 1.61 2H), 2.05 3H), 2.55 J= 7.4 Hz, 2H), 2.88 J= 6.3 Hz, 2H), 4.62 1H), 5.59 1H), 6.40 J= 7.1 Hz, 1H); 3 C NMR (CDC1 3 8 191.8, 169.8, 55.4, 55.0, 34.1, 32.9, 32.8, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 28.8, 28.2, 23.2, 22.7, 14.14; IR (KBr) 3287, 3068, 2919, 2853, 2126, 1655, 1547, 1383, 1168, 725 cm S-trans-trans-Farnesyl-mercaptoethyl diazomethyl ketone (HI 83) (3f) Yellow oil. Yield 45%, 0.45 g. 'H NMR (CDC1 3 8 1.60 6H), 1.67 3H), 1.68 3H), 2.03 8H), 2.58 J= 7.2 Hz, 2H), 2.75 J= 7.2 Hz, 2H), 3.17 J= 7.7 Hz, 2H), 5.09 2H), 5.24 J= 7.3 Hz, 1H), 5.29 1H); 3 C NMR (CDCl 3 6 139.1, 135.2, 131.2, 124.2, 123.6, 120.0, 68.1, 51.8, 39.7, 39.6, 38.7, 34.8, 30.4, 29.8, 29.4, 26.8, 26.5, 26.0, 25.8, 17.8, 16.2, 16.1; IR (KBr) 3095, 2967, 2922, 2855, 2105, 1715, 1645, 1445, 1368, 1318 cm-i; MS (MALDI-TOF) 357 (M +Na).
S-trans-trans-Farnesyl-mercaptomethyl diazomethyl ketone (HI 84) (3g) Yellow oil. Yield 47%. 0.36 g. 'H NMR (CDCl 3 6 1.60 6H), 1.66 3H), 1.68 3H), 2.03 8H), 3.20 4H), 5.09 2H), 5.20 7.8 Hz, 1H), 5.77 1H); 3 C NMR (CDC1 3 140.6, 135.3, 131.2, 124.2,123.6, 118.9, 54.1, 47.2, 39.8, 39.7, 38.8, 31.9, 30.0, 39.8, 26.8, 26.6, 26.4, 25.8, 17.8, 16.2, 16.15; IR (KBr) SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCTIUS99/1 4758 3107, 2966, 2923, 2854, 2105, 1724, 1639, 1449, 1355 cm'1; MS (MALDI-TOF) 343 (M +Na).
N-Ac-S-trans-trans-farnesyl-Cys chioromethyl ketone (HI 368) (4a) Pale yellow solid. Yield 55%, 0.22 grams, m.p. 59-6 1 'H NMR (CDC1 3 8 1.56 611), 1.64 6H), 2.01 3H1), 2.04 (in, 2.85 (ABX, J 6.6, 13.9 Hz, 2H1), 3.14 (mn, 2H1), 4.31 2H1), 4.85 (mn, I1H), 5.05 J =6.9 Hz, 2H1), 5.17 J= 7.7 Hz, 1H), 6.36 (br, IH); 3 C NMR (CDCl 3 8 199.9, 170.0, 140.5, 135.4, 131.3, 124.2, 123.5, 119.2, 60.4, 55.3, 47.3, 39.7, 39.6, 31.9, 29.9, 26.7, 26.4, 25.7, 22.9, 17.7, 16.2, 16.0; IR (KBr) 3300, 3061, 2926, 2852, 2825, 1738, 1633, 1541, 1448, 1421, 1371, 1286, 1078 cm'1; GC/MS 363 (M HC1).
N-Ac-S-trans-geranyI-Cys chioromethyl ketone (HI 127) (4c) Yellow oil. Yield 27%, 0.03 g. rH NMR (CDCl 3 8 1.61 3H), 1.67 3H), 1.68 3H), 2.05 3H1), 2.07 (in, 4H), 2.88 (ABX, J= 5.9, 6.3, 13.7 Hz, 2H), 3.18 (in, 2H), 4.34 (in, 2H), 4.89 J1 6.3 Hz, IlH), 5.07 (in, IlH), 5.21 J 7.8 Hz, ILH); 3 C NMR (CDCl 3 6 199.8, 169.9, 140.4, 131.8, 123.6, 119.2, 55.3, 47.3, 39.7, 39.6, 32.0, 30.0, 29.8, 26.5, 25.8, 23.0, 17.8, 16.3; JR (KBr) 3342, 2970, 2926, 2859, 1741, 1732, 1664, 1651, 1538, 1446, 1379, 1301, 1084 cm'1; GC/MS 295 (M Cl), 205 (farnesyl).
N-Ac-S-(3-methyl-2-butenyl)-Cys chiorometbyl ketone (HI 128) (4d) Off-white solid. Yield 56%, 0.18 g. 'H NMR (CDCL 3 8 1.68 3H), 1.76 3H), 2.06 3H1), 2.89 (ABX, J 6.0, 6.5, 13.8 Hz, 2H), 3.17 (in, 2H), 4.34 (in, 2H), 4.89 J 6.3 Hz, 1H), 5.20 J 7.8 Hz, 1H), 6.32 J 5.5 Hz, 1H); 1 3 C NMR (CDC1 3 8 199.8, 169.9, 136.8, 119.4, 55.4, 47.3, 32.1, 30.2, 25.8, 23.0, 17.9; JR (KBr) 3302, 3060, 2976, 2958, 2927, 2853, 1738, 1635, 1541, 1423, 1371, 1286, 1216, 1078 cm'1; GC/MS 227 (M Cl).
N-Ac-S-dodecyl-Cys chioromethyl ketone (HI 131) (4e) Pale yellow solid. Yield 100%, 0.18 g. m.p. 73-74 0 C. 'HNMR (CDCl 3 )860.88 J 6.7 Hz, 311), 1.26 (in, 18H), 1.57 (in, 2H1), 2.06 3H), 2.54 J =7.3 Hz, 2HI, 2.94 (ABX, J1=6.0, 6.3, 13.9 Hz, 2H1), 4.3 5 (mn, 2H), 4.91 (in, 1IH), 6.31 (br, 1lH); I C NMR (CDCl 3 5 195.2, 165.3, 50.8, 42.7, 29.6, 28.4, 28.2, 27.3, 25.1, 25.0, 24.9, 24.83, 24.8, 24.7, 24.5, 24.1, 18.3, 18.1, 9.5; IR (KBr) 3302, 2924, 2854, 1738, 1660, 1537, 1456, 1377, 1261, 1165, 1095, 1040 cm'1; MIS (MALDI-TOF), 364.9 (M 328.9 (M Cl).
S-trans-trans-Farnesyl-2-mercaptoethyl chioromethyl ketone (HI 125) (41) Yellow oil. Yield 68%, 0.36 g. 'H1 NMR (CDC1 3 8 1.60 6H), 1.67 3H), 1.68 3H), 2.03 (in, 8H), 2.74 J 6.6 Hz, 2H), 2.89 J 6.6 Hz, 21-I? 3.18 (d, J1=7.5 Hz, 2H), 4. 10 2H), 5.09 (mn, 2H), 5.23 J1=7.8 Hz, I1H); 'C NMR (CDCl 3 8 200.9, 139.2, 135.3, 131.2, 124.2, 123.6, 120.0, 48.3, 40.1, 39.7, 39.6, 29.8, 26.8, 26.5, 25.8, 24.8, 17.8, 16.2, 16.1; JR (KBr) 2964, 2925, 2852, 1726, 1441, 1379, 1351, 1110, 1077 cnf'; GC/MS 342 307 (M Cl), 205 (farnesyl); MIS (MALDI-TOF) 342.6 (Me).
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 31 S-trans-trans-Farnesyl-mercaptomethyl chloromethyl ketone (HI 126) (4g) Clear oil. Yield 17%, 0.10 g. 'H NMR (CDCl 3 6 1.60 6H), 1.66 3H), 1.68 3H), 2.03 8H), 3.16 J= 7.8 Hz, 2H), 3.34 2H), 4.34 2H), 5.09 2H), 5.18 1H); 13C NMR (CDCI 3 5 197.2, 140.9, 135.3, 131.1, 124.1, 123.5, 118.6, 46.2, 39.7, 39.6, 38.4, 37.4, 37.1, 32.0, 31.8, 29.8, 26.7, 26.5, 26.3, 25.3, 17.7, 16.2, 16.1; IR (KBr) 3444, 2965, 2926, 2859, 1732, 1712, 1664, 1446, 1384, 1243, 1108 GC/MS 328 294 (M C1), 205 (farnesyl).
S-Dodecyl-Cys-OCH 3 Light yellow oil. Yield 61%, 1.85 g. 'H NMR (CDC1 3 8 0.88 J= 6.6 Hz, 3H), 1.26 20H), 2.53 J= 7.5 Hz, 2H), 2.76 (m, 1H), 2.91 1H), 3.67 1H), 3.75 3H); IR (KBr) 3381, 2924, 2854, 1743, 1466, 1437, 1196, 1175 GC/MS 303 N-Boc-S-dodecyl-Cys-OCH 3 Clear oil. Yield 100%, 2.82 g. 'H NMR (CDCl 3 8 0.88 J= 7.1 Hz, 3H), 1.25 20H), 1.45 9H), 2.51 J= 7.5 Hz, 2H), 2.95 J 5.2 Hz, 1H), 3.76 3H), 4.52 1H), 5.37 1H); IR (KBr) 2977, 2932, 1814, 1759, 1062 GC/MS 403 286, 215, 57.
N-Boc-S-dodecyl-Cys-OH Yellow oil. Yield 80%, 2.65 g. 'H NMR (CDC1 3 8 0.88 J 6.6 Hz, 3H), 1.24 20H), 1.45 9H), 2.52 J 7.4 Hz, 2H), 2.96 J 4.9 Hz, 2H), 4.50 1H), 5.38 (br, 1H); 3 C NMR (CDC1 3 6 175.0, 156.0, 80.0, 53.0, 34.5, 34.1, 32.9, 32.6, 32.0, 29.7, 29.6, 29.4, 29.2, 28.8, 28.2, 22.8, 14.0; IR (KBr) 3328, 2922, 2852, 1719, 1503, 1368, 1172, 1052 cm N-Boc-S-dodecyl-Cys diazomethyl ketone Light yellow oil that solidified upon standing. Yield 59%, 0.56 g. 'H NMR (CDC1 3 5 0.88 J= 6.7 Hz, 3H), 1.26 18H), 1.46 9H), 1.58 2H), 2.53 2H), 2.89 2H), 4.30 1H), 5.61 (br, 1H); IR (KBr) 3323, 2924, 2853, 2108, 1718, 1647,1499, 1369, 1168 cm MS (MALDI-TOF) 386.5 (M N 2 N-Boc-S-dodecyl-Cys chloromethyl ketone (HI 129) Clear oil that solidified upon standing. Yield 100%, 0.57 g. m.p. 43-49 H NMR (CDC1 3 8 0.88 3H), 1.26 18H), 1.45 9H), 1.57 2H), 2.53 2H), 2.93 2H), 4.37 1H), 4.60 1H), 5.37 (br s, 1H); "C (CDC1 3 8 172.5, 130.8, 56.9, 53.2, 52.5, 47.4, 34.5, 33.2, 32.9, 32.8, 32.0, 29.7, 29.6, 29.5, 29.4, 29.2, 28.8, 28.6, 28.3, 28.0 22.8, 14.2; IR (KBr) 3363, 2926, 2854, 1713, 1497, 1468, 1367, 1252, 1167
-I
cm S-Dodecyl-Cys chloromethyl ketone hydrochloride (HI 252) Silverywhite solid. Yield 81%, 0.14. m.p. 118-119 OC (decomp.). 'H NMR (DMSO-d) 0.84 J= 6.7 Hz, 3H), 1.23 18H), 1.51 2H), 2.57 J= 7.3 Hz, 2H), 2.96 (dd, J= 6.9, 14.4 Hz, 1H), 3.09 (dd, J= 5.8, 14.4 Hz, 1H), 4.44 J= 6.2 Hz, 1H), 4.84 2H), 8.58 (br, 3H); 13C NMR (DMSO-d 6 6 193.2, 51.4, 43.9, 27.3, 27.1, 26.2, 24.9, 24.6, 24.4, 24.0, 18.0, 9.8; IR (KBr) 2953, 2922, 2852, 1738, 1470, 1385, 1149 cm SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCT/US99/1 4758 32 S-trans-trans-Farnesyl-Cys-OCH 3 (10) Clear oil. Yield 68%,2.3 1 g. 'H NMR (CDCl 3 6 1.59 6H), 1.67 6H1), 2.08 (in, 8H), 2.68 (dd, J 13.5 Hz, I1H), 2.89 (dd, J 4.8, 13.5 Hz, I1H), 3.19 (in, 2H), 3.61 (mn, ILH), 3.75 3H), 5.08 (mn, 2H), 5.21 J =7.9 Hz, I1H); JR (KBr) 3 348, 3 376, 3 314, 2978, 2922, 2860, 1746, 1684, 1452, 13 95, 1209, 1168, 843 cm'1; GC-MS 3 39 270, 202, 13 81, 69.
N-Boc-Gly-S--trans-trans-farnesyl-Cys-OCH3 Yellow oil. Yield 61%, 2.27 g. 'H NMR (CDCI 3 6 1.45 9H), 1.60 6H), 1.66 3H), 1.68 3H), 1.94-2.09 (mn, 8H), 2.81 (ABX, J 6.2, 13.9 Hz, 2H), 3.16 (in, 2H), 3.76 (s, 3H), 3.85 J 5.5 Hz, 2H), 4.80 (mn, 1 5. 10 (mn, 2H), 5.18 (in, 2H), 6.86 (br d, J =7.3 Hz, 1H1); MS (MAIDI-TOF), 496.5 N-Boc-Gly-S-trans-trans-farnesyl Cys-Oll (11) Clear oil. Yield 61%, 0.74 g. 'Hl NMR (CDCl 3 5 1.45 9H1), 1.60 6H), 1.65 6H), 1.95-2.20 (mn, 8H1), 2.80-3.08 (in, 2H), 3.10-3.27 (mn, 2H), 3.70-3.90 (in, 2H), 3.95-4.10 (mn, 1H), 4.75-4.95 (in, IH), 5.08 (mn, 2H), 5.20 (mn, 1H), 5.41 I 7. 10 (in, I1H); IR (KBr), 3338, 2979, 2930, 1725, 1660, 1525, 1241, 1172 cmf'; MS (MALDI-TOF), 505.3 (M +Na~) N-Boc-Gly-S-trans-trans-farnesyl-Cys diazomethyl ketone (HI 401) (12) Yellow oil. Yield 53 0.21 g. H NMR (CDCl 3 6 1.46 9H), 1.60 6H), 1.67 6H), 1.97-2. 10 (mn, 8H), 2.85 (in, 2H), 3.19 mr, 2H), 3.82 (mn, 2H1), 4.63 (in, 1H), 5.07-5.24 (in, 3H), 5.68 1H), 6.93 (in, 1H); 3C NMR (CDCl 3 6 169.3, 140.1, 135.4, 131.4, 130.9, 128.8, 124.2, 123.1, 119.4, 80.6, 68.0, 65.9, 55.2, 54.8, 52.8, 48.3, 44.5, 39.7, 33.0, 31.7, 31.0, 30.2, 29.7, 28.3, 26.7, 26.4, 25.7, 23.5, 17.7, 16.2, 16.0; JR (KBr), 3318, 3084, 2983, 2916, 2859, 2105, 1669, 1510, 1369 cmI N-Boc-Gly-S-trans-trans-farnesyh-Cys chioromethyl ketone (HI 130) (13) Yield 100%, 0.22 g. 'H NMR (CDCl 3 6 1.45 9H), 1.60 6H), 1.68 (s, 611), 1.96-2.09 (in, 8H), 2.8 1-2.97 (in, 2H), 3.10-3.24 m, 2H1), 3.82 (in, 2H), 4.33 2H1), 4.89 (in, 1H), 5.07-5.22 (mn, 3H), 6.94 (in, I1H); 'C NMR (CDCI 3 6 199.7, 169.9, 156.0, 140.4, 135.3, 131.2, 124.2, 123.5, 123.1, 119.2, 111.5, 109.7, 80.5, 60.3, 55.4, 53.1, 51.8, 47.4, 44.2, 41.1, 39.6, 39.6, 31.8, 29.9, 28.2, 26.7, 26.4, 25.7, 21.0, 17.7, 16.1, 16.0, 14.1; JR (KBr), 3309, 2987, 2925, 1695, 1514, 1175 cmI' MS (MALDI-TOF), 379.4 (M Boc Cl).
N-Ac-S-methyl-cysteine chloromethyl ketone (4h, HI 314) Yellow oil.
Yield 10%. 'H1 NMR (CDCl 3 6 2.04 3H), 2.11 3H), 2.98 (ABX, J= 6.0, 6.3, 14.0 Hz, 2H), 4.36 (in, 2H), 4.87 (mn, 1H), 6.41 (hr d, 1H); 3 C NMR (CDCl 3 6 16. 1, 22.9, 35.0, 47.4, 55.0, 170.3, 200.0; GCIMS 209 IR (KBr) 3278, 2922, 1741, 1659, 1537, 1429, 1209 cmn'.
N-Ac-S-ethyl-cysteine chioromethyl ketone (4i, HIl 315) Yellow solid.
Yield 45%. 'Hl NMR (CDC1 3 6 1.24 J =7.4 Hz, 3H), 2.03 3H), 2.54 J= 7.3 Hz, 2H), 2.93 (ABX, J= 6.0, 6.3, 14.0 Hz, 2H), 4.34 (in, 2H1), 4.88 (mn, 1H), 6.36 (br d, IH); 3 C NMR (CDC 3 6 10.0, 18.3, 22.0, 27.9, 42.7, 50.7, 165.5, 195.4; GC/MS 194 (M-CH)CH 3 IR (KBr) 3299, 2927, 2872, 1740, 1659, 1537, 1535, 1425, 1371 cm' SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCTIUS99/1 4758 33 N-Ac-S- Iropy1-cysteine chiorometbyl ketone (4j, HIl 369) Yellow semisolid. Yield 20%. H NMR (CDCl 3 5 0.96 J 7.3 Hz, 3H), 1.57 (in, 2H), 2.03 (s, 3H), 2.50 J 7.3 Hz, 2H), 2.91 (in, 2H), 4.3 3 (in, 2H), 4.77 (in, 1 6.3 2 (br d, 1H); 1 3 C NMR (CDCl 3 6 13.2, 22.6, 22.7, 32.5, 34.5, 47.6, 55.5, 170.6, 200.0; GC/MS 23 8 l) IR (Klr) 3 020, 2976, 293 3, 1740, 1676, 1518, 1423, 1215 cm- N-Ac-S-butyl-cysteine chioromethyl ketone (4k, HIl 363) Yellow solid.
Yield 65%. m.p. 75-76 'H1 NMR (CDCl 3 6 0.90 J =7.1 Hz, 3H), 1.3 8 (mn, 2H1), 1.52 (in, 2H), 2.04 3H), 2.53 J 7.3 Hz, 2H), 12.98 (ABX, J 6.0, 6.3, 14.0 Hz, 2H), 4.28 (in, 2H), 4.93 (in, 1H), 6.21 (br d, 1H); 3 C NMR (CDCl 3 6 14.2, 22.9, 31.4, 32.4, 32.9 47.4, 55.4, 170.1, 200.0; GC/MS 215 MS (MALDI-TOF) 250 IR (KBr) 3425, 3020, 1732, 1651, 1537, 1466 cm'1.
N-Ac-S-pentyl-cysteine chioromethyl ketone (41, HIl 224) Yellow solid.
Yield 41% yield. m.p. 74-75 0 C. '11I NMR (CDCl 3 6 0.86 J =6.8 Hz, 3H), 1.2-1.4 (mn, 4H), 1.55 (mn, 2H), 2.04 3H), 2.52 J =7.5 Hz, 2H), 2.93 ABX, J= 6.3, 13.5 Hz, 2H), 4.32 (in, 2H), 4.89 (in, 1H1), 6.26 (br d, 1H1); 3 C NMR
(CDC
3 6 14.1, 22.7, 22.9, 28.7, 29.2, 29.6, 31.9, 32.9, 47.4, 55.4, 170.1, 200.0; GC/MS 266 MS (MALDI-TOF) 266 IR (KBr) 3296, 2918, 2850, 1738, 1660, 1539, 1464 cmI.
N-Ac-S-hexyl-cysteine chioromethyl ketone (4m, HI 357) Yellow solid.
Yield 44%. m.p. 75-77 'H NMR (CDCl 3 6 0.87 J 6.7 Hlz, 3H), 1.2-1.4 (mn, 6H), 1.56 (in, 2H1), 2.05 3H1), 2.53 J 7.4 Hz, 2H), 2.93 (ABX, J =5.8, 13.9 Hz, 2H1), 4.3 5 (in, 2H1), 4.8 9 (in, I1H), 6.3 6 (br d, I 1 3 C NMR (CDC1 3 6 14.0, 22.5, 22.9, 28.4, 29.4, 29.6, 31.3, 32.8, 47.4, 55.4, 170.1, 200.0; GC/MS 243 IR (KBr) 3304, 3053, 2951, 2926, 2870, 1738, 1639, 1537, 1425, 1371, 1283 cm-1 N-Ac-S-heptyl-cysteine chioromethyl ketone (4n, HIl 263) Yellow solid.
Yield 19%. in.p. 77-8 1 0 C. 'H1 NMR (CDC 3 6 0.87 J =6.6 Hz, 3H1), 1.2-1.4 (in, 8H), 1.54 (in, 2H1), 2.03 3H), 2.51 J 7.3 Hz, 2H), 2.92 (ABX, J =5.8, 6.3, 13.7 Hz, 2H), 4.32 (in, 2H), 4.88 (in, 1H), 6.25 (br d, 1H); 3 C NMR (CDC 3 6 14.1, 22.5, 22.9, 28.6, 28.7, 29.4, 31.6, 32.7, 32.8, 47.4, 55.4, 170.1, 200.0; GC/MS 259 MS (MALDI-TOF) 294 IR (KBr) 3306, 2918, 2922, 1737, 1641, 1537, 1466, 1372, 1283, 1134 cm N-Ac-S-octyl-ysteine chioromethyl ketone (4o, HIl 352) Yellow solid.
Yield 30% yield. m.p. 76-77 'H NMR (CDC1 3 6 0.88 J 6.9 Hz, 3H), 1.2-1.4 (in, 10H), 1.55 (in, 2H), 2.05 3H), 2.53 J= 7.4 Hz, 2H), 2.93 (mn, 2H), 4.35 (in, 2H), 4.87 (in, 1H1), 6.36 (br d, 1H1); 13 C NMR (CDC1 3 6 14.0, 22.5, 28.4, 29.3, 31.3, 32.7, 32.9, 47.3, 55.3, 170.0, 199.7; GCIMS 271 (M-HCI); IR (KBr) 3300, 3055, 2918, 2852, 1738, 1639, 1537, 1425, 1371, 1283 cm' SUBSTITUTE SHEET (RULE 28) WO 00/00469 PCT/US99/14758 34 N-Ac-S-nonyl-cysteine chloromethyl ketone (4p, HI 364) Yellow solid.
Yield 35%. m.p. 78-81 OC. 'H NMR (CDCl 3 6 0.86 J= 6.5 Hz, 3H), 1.2-1.4 12H), 1.58 2H), 2.06 3H), 2.56 J= 7.3 Hz, 2H), 2.98 (ABX, J= 6.1, 6.3, 13.8 Hz, 2H), 4.36 2H), 4.86 1H), 6.41 (br d, 1H); 13C NMR (CDC13) 6 14.1, 22.6, 22.9, 28.7, 29.1, 29.2, 29.4, 31.8, 32.7, 32.8, 47.4, 55.4, 170.2, 200.0; GC/MS 285 (M-HC1); MS (MALDI-TOF) 322 IR (KBr) 3302, 2920, 2850, 1738, 1643, 1537, 1394 cm'.
N-Ac-S-decyl-cysteine chloromethyl ketone (4q, HI 371) Yellow solid.
Yield 10%. m.p. 80-81 oC. 'H NMR (CDC13) 6 0.86 J= 6.7 Hz, 3H), 1.2-1.4 14H), 1.59 2H), 2.06 3H), 2.56 J 7.3 Hz, 2H), 2.98 (ABX, J= 6.3, 13.7 Hz, 2H), 4.28 2H), 4.93 1H), 6.21 (br d, 1H); 13C NMR (CDC 3 6 14.1, 22.7, 22.9, 28.7, 29.2, 29.3, 29.4, 29.5, 31.9, 32.8, 47.4, 55.4, 170.1, 200.0; MS (MALDI-TOF) 301 IR (KBr) 3302, 2920, 2850, 1736, 1635, 1539, 1467 -1 cm.
N-Ac-S-undecyl-cysteine chloromethyl ketone (4r, HI 321) Yellow solid. Yield 25%. m.p. 85-86 'H NMR (CDC13) 6 0.86 J 6.7 Hz, 3H), 1.2-1.4 16H), 1.59 2H), 2.06 3H), 2.56 J= 7.3 Hz, 2H), 2.98 (ABX, J 6.0, 6.3, 13.7 Hz, 2H), 4.28 2H), 4.93 1H), 6.21 (br d, 1H); 13C NMR (CDC13) 8 14.1, 22.7, 22.9, 28.7, 29.2, 29.3, 29.4, 29.5, 29.6, 31.9, 32.8, 32.9, 47.4, 55.4, 170.1, 200.0; GC/MS 313 MS (MALDI-TOF) 313 IR (KBr) 3305, 2918, 2850, 1738, 1651, 1537, 1466 cm N-Ac-S-tridecyl-cysteine chloromethyl ketone (4s, HI 323) Yellow solid. Yield 22%. m.p. 83-84 oC. 'H NMR (CDC1 3 6 0.87 J 6.3 Hz, 3H), 1.2-1.4 20H), 1.59 2H), 2.06 3H), 2.56 J= 7.2 Hz, 2H), 2.98 (ABX, J 5.8, 6.0, 14.0 Hz, 2H), 4.28 2H), 4.93 1H), 6.21 (br d, 1H); 'C NMR (CDC1 3 8 14.1, 22.7, 23.0, 28.8, 29.2, 29.4, 29.4, 29.5, 29.6, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 341 (M-HC1); MS (MALDI-TOF) 379 IR (KBr) 3307, 2916, 2850, 1737, 1651, 1537, 1466, 1402, 1282 cm N-Ac-S-tetradecyl-cysteine chloromethyl ketone (4t, HI 354) Yellow solid. Yield 32%. m.p. 79-80 'H NMR (CDC1 3 8 0.88 J 6.7 Hz, 3H), 1.2-1.4 22H), 1.57 2H), 2.06 3H), 2.51 J= 7.3 Hz, 2H), 2.94 (ABX, J 6.0, 6.3, 13.9 Hz, 2H), 4.35 2H), 4.90 1H), 6.30 (br d, 1H); 3 C NMR (CDC1 3 5 14.1, 22.7, 22.9, 28.7, 29.2, 29.35, 29.4, 29.5, 29.6, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 355 (M-HCI); IR (KBr) 3302, 3259, 2916, 2848, 1738, 1660, 1537, 1464, 1373, 1317 cm 1 N-Ac-S-pentadecyl-cysteine chloromethyl ketone (4u, HI 225) Yellow solid. Yield 25%. m.p. 86-89 'H NMR (CDC1 3 6 0.86 J= 6.5 Hz, 3H), 1.2-1.4 24H), 1.55 2H), 2.03 3H), 2.51 J= 6.2 Hz, 2H), 2.91 (ABX, J 6.0, 6.3, 14.0 Hz, 2H), 4.34 2H), 4.88 1H), 6.33 (br d, 1H); 3 C NMR (CDC1 3 8 14.1, 22.7, 23.0, 28.8, 29.0, 29.2, 29.4, 29.5, 29.7, 30.7, 31.9, 32.2, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 369 (M-HC1); MS (MALDI-TOF) 407 IR (KBr) 3307, 3124, 2916, 2850, 1738, 1651, 1533, 1487, 1404, 1284 cm SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCTIUS99/1 4758 N-Ac-S-hexadecyl-cysteine Ichioromethyl ketone (4v, HI 366) Yellow solid. Yield 18%. m.p. =87-88 'H NMR (CDC1 3 5 0.86 J 6.7 Hz, 3H1), 1.2-1.4 (in, 26H), 1.55 (mn, 2H), 2.03 3H), 2.51 J= 7.3 Hz, 2H1), 2.98 3(ABX, J 5.8, 6.0, 14.0 Hz, 2H4), 4.32 (mn, 4.93 (in, lH), 6.26 (br d, 111); 1 C NMR
(CDC
3 8 14.2, 22.7, 23.0, 28.8, 29.0, 29.2, 29.4, 29.5, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 383 MS (MALDI-TOF) 382 (M-HCl); IR (KBr) 3259, 2916, 2848, 1740, 1660, 1539, 1471, 1432, 1134 cin'.
N-Ac-S-octadecyl-cysteine chioroniethyl ketone (4w, HI 370) Yellow solid. Yield 78%. in.p. 84-86 'H NMR (CDCl 3 8 0.88 J 6.7 Hz, 311), 1.2-1.4 (in, 30H), 1.57 (mn, 2.06 3H1), 2.53 J= 7.4 Hz, 2H), 2.94 3(ABX, J 5.8, 6.3, 13.7 Hz, 2H), 4.35 (mn, 4.90 (in, 1H), 6.31 (br d, 3 C NMR (CDC1 3 8 14.2, 22.7, 23.0, 28.8, 29.2, 29.35, 29.4, 29.5, 29.6, 29.7, 31.9, 32.8, 32.9, 34.4, 47.3, 55.4, 170.0, 200.0; IR (KBr) 3313, 2916, 2850, 1738, 1651, 1537, 1466, 1385, 1281, 1254 cin'.
N-Ac-S-eicoyl-eysteinc chioromethyl ketone (4x, HI 226) Yellow solid.
Yield 11%. in.p. 84-89 'H NMR (CDCl 3 8 0.87 J 6.6 Hz, 3H1), 1.2-1.4 (in, 34H1), 1.55 (in, 2H1), 2.04 3H1), 2.52 J =7.9 Hz, 2H), 2.92 (ABX, J 7.7, 14.0 Hz, 21-1), 4.32 (in, 2H), 4.92 (in, 111), 6.28 (br dl, 111); 1 3 C NMR (CDC1 3 8 14.2, 22.7, 23.0, 28.7, 29.2, 29.4, 29.5, 29.6, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.0, 200.0; MS (MALDI-TOF) 477 IR (KBr) 3307, 2918, 2850, 1736, 1662, 1541, 1464,1261,1097 cm-1 N-Ac-S-docosyl-cysteine chioromethyl ketone (4y, HI 322) Yellow solid. Yield 15%. m.p. 95-97 'H NMR (CDCl 3 8 0.88 J 6.5 Hz, 311), 1.2-1.4 (mn, 3811), 1.55 (mn, 211), 2.04 3H), 2.52 J1 7.8 Hz, 2H), 2.92 (ABX, J 6.0, 6.3, 14.0 Hz, 211), 4.32 (in, 211), 4.92 (in, 111), 6.28 (br d, 111); 3 C NMR (CDCl 3 8 14.2, 22.7, 23.0, 28.8, 29.2, 29.4, 29.5, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; MS (MALDI-TOF) 493 (M+2-CI+Na); IR (KBr) 3259, 2918, 2848, 1740, 1660, 1537, 1471, 1261, 1099 cm'1.
N-Ac-S-alyI-cysteine chioromethyl ketone (111-419) Pale yellow solid: 1H NMR (CDC 3 5 2.02 311), 2.85 (in, 211), 3.12 211), 4.31 (in, 2H1), 4.87 (mn, 111), 5.12 (dd, I1H), 5.16 111), 5.74 (in, I 6.3 2 (br, 111).
N-Ac-S-t-butyl-cysteine chioromethyl ketone (HI-349) Pale yellow solid: 'H NMR (CDCl 3 8 1.24 911), 1.97 311), 2.90 (dd, 211), 4.27 (in, 211), 4.87 (in, 111), 6.32 (br, 11-1); MS (El) m/z 251 (Mt).
N-Ac-S-2-methylpropylceysteine chioromethyl ketone (111-391) Pale yellow solid: I H NMR (CDCl 3 5 0.94 (in, 611), 1.74 (in, 111), 2.01 311), 2.40 (d, 211), 2.87 211), 4.3 3 (in, 211), 4.83 (in, 11H), 6.51 11H); MS (El) m/z 252 (Me).
N-Ac-S-2,2-dimethylpropyl-cysteine chioromethyl ketone (HI-421) Pale yellow solid: I H NMR (CDCl 3 8 1.32 911), 2.06 311), 3.15 (in, 211), 3.45 (mn, 211), 4.34 2H1), 4.94 (in, 111), 6.42 11H); MS (El) m/z 227 (M t Bu).
SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCT/US99/1 4758 36 N-Ac-S-3-methylbutyl-cysteine chioromethyl ketone (HI-387) Pale yellow solid: I'H NMR (CDCl 3 8 0.89 6H1), 1.44 (in, 1H), 1.62 (in, 211), 2.04 (s, 311), 2.53 2H), 2.93 (mn, 211), 4.34 (in, 2H), 4.88 (in, 11-1), 6.30 1H1); MIS (El) m/z 229 (M -Cl).
N-Ac-S-2-ethylbutyl-cysteine chioromethyl ketone (111-390) Pale yellow solid: I'H NMR (CDCl 3 8 0.83 (in, 61-1), 1.35 (in, 511), 2.03 311), 2.51 (d, 2H), 2.90 (in, 2H), 4.32 2H1), 4.87 (in, 1H1), 6.34 1H1); MIS (EI) m/z 243 (M Cl).
N-Ac-S-cyclopropylmethyl-cysteine chioromethyl ketone (111-507) Pale yellow solid: 'H NMR (CDCl 3 6 0.57 4H), 0.95 (mn, 111), 2.03 3H), 2.45 2H), 2.97 (mn, 2H), 4.33 2H), 4.89 (mn, 1H), 6.34 11H).
N-Ac-S-cyclobutylmethyl-cysteine chioromethyl ketone (111-385) Pale yellow solid: 'H1 NMR (CDCl 3 6 1.83 (in, 7H1), 2.02 3H), 2.58 211), 2.89 (mn, 2H), 4.32 2H), 4.84 (mn, 1H), 6.32 1H); MS (El) m/z 227 (M Cl).
N-Ac-S-cyclohexylmethyl-cysteine chioromethyl ketone (111-386) Pale yellow solid: H NMR (CDCl 3 6 0.90 (in, 211), 1.25 (in, 4H), 1.41 (in, 411), 1.70 (in, IH), 2.04 311), 2.40 2H1), 2.89 (in, 2H), 4.34 (in, 211), 4.86 (in, 111), 6.35 (d, 1M).
N-Ac-S-benzyl-cysteine chloromethyl ketone (111-251) Pale yellow solid: H NMR (CDCl 3 6 1.98 311), 2.82 (in, 2H1), 3.70 211), 4.08 2H), 4.82 (mn, IH), 6.18 111), 7.29 (mn, 511).
N-Ac-S-4-methoxybenzyl-cysteile chioromethyl ketone (111-349) Pale yellow solid: I'HNMR (CDCl 3 6 1.91 3H1), 2.78 (in, 211), 3.62 3H), 3.73 (s, 211), 4.12 2H), 4.74 (in, 111), 6.07 111), 6.80 (mn, 211), 7.18 (mn, 211); MS (El) m/z 279 (M -Cl).
N-Ac-S-benzyloxycarbonyl-cysteifle chioromethyl ketone (111-389) Pale yellow solid: '1H NMR (CDCl 3 6 1.98 311), 3.36 (in, 211), 4.31 211), 5.01 (in, 211), 5.42 (in, 111), 6.43 111), 7.35 (in, 511).
N-Ac-S-diphenylnethyl-cysteifle chioromethyl ketone (111-418) Pale yellow solid: 'H NMR (CDC1 3 6 2.00 (in, 411), 3.37 (mn, 211), 4.34 211), 5.02 (in, 111), 6.5 3 11H), 7.3 0 (in, 1011).- N-Ac-S-trityl-cysteine chioromethyl ketone (111-350) Pale yellow solid: I H NMR (CDC1 3 5 1.92 311), 2.73 (in, 211), 3.89 211), 4.40 (in, 111), 5.82 1H1), 7.21 (mn, 15H1).
SUBSTITUTE SHEET (RULE WO 00/00469 WO 0000469PCTIUS99/1 4758 37 N-Ac-S-2-naphthylmethyl-cysteine chioromethyl ketone (111-392) Pale yellow solid: I H NMR (CDCl 3 6 1.89 2.81 (in, 3.84 2H), 4.13 21-1), 4.83 (in, 1H), 6.10 1H1), 7.43 (mn, 2H), 7.66 111), 7.72 (in, 4H).
N-Ac-O-dodecyl-serine chioromethyl ketone (111-489) White solid: H NMR (CDCl 3 860.88 3H), 1.26 (in, 20H1), 2.05 311), 3.41 3.57 (mn, 1H), 3.88 (in, 111), 4.29 2H), 4.90 (mn, 11H), 6.32 111).
N-Boc-O-dodecyl serine chioromethyl ketone (111-266) Pale yellow solid: H NMR (CDCl 3 6 0.88 3H), 1.26 (in, 20H), 1.46 9H), 3.41 2H), 3.50 (mn, 11-1), 3.57 (dd, 11H), 4.37 2H), 4.56 (in, 1H1), 5.21 111); MIS (El) m/z 357 (M -Cl).
N-Propyloxycarbonyl-S-dodecyl-cysteine chioroniethyl ketone (HI- 413) Pale yellow solid: 'H4 NMR (CDCI 3 8 0.92 (mn, 6H), 1.25 (mn, 20H), 1.60 (mn, 2H1), 2.52 21-1), 2.91 4.01 2H), 4.45 2H), 4.66 (mn, 1H), 5.48 11H); MS (El) m/z 371 (M Cl).
N-Benzyloxycarbonyl-S-dodecyl-cysteine chioromethyl ketone (H1- 320) Pale yellow solid: H NMR (CDCl 3 6 0.86 1.27 (mn, 20H), 2.49 (t, 2H1), 2.91 2H), 4.32 2H), 4.70 (in, 11-1), 5.19 2H), 5.59 7.32 (s, MS (El) m/z 419 (M Cl).
N-9-FluorenylmethyloxycarbonyFS-dodecyl-cysteifle chioromethyl ketone (111-398) Pale yellow solid: 'H NMR (CDCl 3 6 0.87 1.24 (mn, 1811), 1.52 (in, 211), 2.52 211), 2.93 (in, 21-1), 4.22 1H1), 4.28 211), 4.46 (in, 211), 4.68 (in, 111), 5.59 111), 7.35-7.77 (in, 8H1).
N-3-DimethylaminobenzoyI-S-dodecyl-cysteine chioromethyl ketone (111-268) Pale yellow solid: I'H NMR (CDC1 3 6 0.94 311), 1.26 (mn, 2011), 2.54 211), 3.01 3.93 611), 4.13 2H1), 4.68 (mn, 111), 5.53 111), 7.00 (dd, 11H), 7.40 (in, 3H1).
N-Ac-S-dodecyl-cysteine bromomethyl ketone (111-488) Pale yellow solid: I'H NMR (CDCl 3 6 0.84 311), 1.22 (in, 1811), 1.53 (mn, 211), 2.02 31-1), 2.50 211), 2.92 (mn, 2H1), 4.12 211), 4.89 (in, 11-1), 6.44 1H1).
N-Ac-S-dodecyl-Cys-N(OCH 3
)-CH
3 (111-267) Pale yellow oil: H NMR (CDCl 3 6 0.87 3H1), 1.25 (mn, 2011), 2.02 311), 2.51 211), 2.82 (in, 211), 3.22 311), 3.79 3H1), 5.17 (mn, 1H1), 6.38 111); MS (El) m/z 314 (M N(0C1 3 )C11 3 N-Ac-S-dodecyl-Cys-H (111-274) White solid: I'H NMR (CDC1 3 8 0.88 31-1), 1.26 (mn, 1811), 1.58 (mn, 2H1), 2.09 311), 2.54 211), 3.00 (mn, 21-1), 4.63 (in, 111), 6.3 7 111), 9.6 5 11H).
SUBSTITUTE SHEET (RULE WO 00/00469 PCT/US99/14758 38 N-Ac-S-dodecyl-Cys-CH 2 -SPh (HI-269) Pale yellow solid: 'H NMR
(CDCI
3 5 0.88 3H), 1.25 18H), 1.53 2H), 1.97 3H), 2.46 2H), 2.2 2H), 5.16 1H), 5.43 2H), 6.16 1H), 7.33 N-Ac-S-dodecyl-Cys-CH 2 -S-2-naphthyl (HI-302) Pale yellow solid: 1H NMR (CDCl 3 5 0.81 3H), 1.16 18H), 1.39 2H), 1.84 3H), 2.36 (t, 2H), 2.77 2H), 5.18 1H), 5.59 2H), 6.08 1H), 7.43 3H), 7.73 (m, 4H).
N-Ac-S-dodecyl-Cys-CH 2
-S-CH
2
CH
2
CO
2 H (HI-273) White solid: 'H NMR (CDCl 3 8 0.88 3H), 1.26 18H), 1.33 2H), 2.07 3H), 2.54 2H), 2.77 4H), 2.97 2H), 3.48 2H), 5.02 1H), 6.44 1H), 8.04 (br, 1H).
Example 3 Cytotoxicitv of alkvl ketone compounds The cytotoxicity of the alkyl ketone compounds against tumor cells was evaluated in leukemic cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
Cytotoxicity Assay Cytotoxicity of various compounds against tumor cells was performed using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Boehringer Mannheim Corp., Indianapolis, IN). Unless otherwise specified, all cell lines were obtained from the American Type Culture Collection (ATCC).
Briefly, exponentially growing cells were seeded into a 96-well plate at a density of 2.5 x 10 4 cells/well and incubated for 36 hours at 37°C prior to drug exposure.
On the day of treatment, culture medium was carefully aspirated from the wells and replaced with fresh medium containing the indicated compound at concentrations ranging from 0.1 to 250 LM. Triplicate wells were used for each treatment.
Human leukemic cell lines (NALM-6, MOLT-3) glioblastoma cells (U373) and human breast tumor cell lines (BT20 and MDA-MB-231) were obtained from the American Type Culture Collection and maintained as a continuous cell line in Dulbecco's modified Eagles's medium supplemented with fetal bovine serum and antibiotics.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 39 The cells were incubated with the various compounds for 24-36 hours at 37°C in a humidified 5% CO 2 atmosphere. To each well, 10 p.1 ofMTT (0.5 mg/ml final concentration) was added and the plates were incubated at 37 0 C for 4 hours to allow MTT to form formazan crystals by reacting with metabolically active cells.
The formazan crystals were solubilized overnight at 37°C in a solution containing SDS in 0.01 M HC1. The absorbence of each well was measured in a microplate reader (Labsystems) at 540 nm and a reference wavelength of 690 nm.
To translate the OD 540 values into the number of live cells in each well, the OD 540 values were compared to those on standard OD 540 versus cell number curves generated for each cell line. The percent survival was calculated using the formula: live cell number [test] Survival X 100 live cell number [control] The IC 5 0 values were calculated by non-linear regression analysis and are shown below in Tables 1 6.
Table 1. Structure and activities of S-alkyl cysteine diazo and chloromethyl ketone derivatives against Nalm-6 (B-lineage ALL), Molt-3 (Tlineage ALL), BT-20 (breast cancer), PC-3 (prostate cancer) and U-373 (glioblastoma) cell lines.
S
R, X 0 No. HI R 4
R
3 R IC50 (pM) No. Nalm-6 Molt-3 BT-20 PC-3 U-373 B-lineage T-lineage Breast Prostate Glioblas ALL ALL Cancer Cancer -toma 12 401 Boc- trans,trans-Famesyl CH=N 51.3 84.5 95.1 90.6 >100 3b 82 Boc trans,trans-Farnesyl CH=N 49.8 50.1 >100 >100 >100 3a 367 Ac trans,trans-Famesyl CH=N 30.3 32.2 >100 >100 >100 3c 122 Ac irans-Geranyl CH=N >100 >100 >100 >100 >100 SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCT[US99/1 4758 3d 123 Ac 3-Methyl-2-butenyl CH=N >100 >100 >100 >100 >100 3e 348 Ac Dodecyl CH=N 15.4 22.9 97.9 >100 >100 13 130 Boc- trans rans-Fanesyl CH 2 12.9 17.5 >100 >100 71.3 4b 124 Boc irans,trans-Famesyl CH 2 10.7 7.7 >100 >100 >100 4a 368 Ac trans, trans-Famcsyl CH 2 3.0 1.4 55.8 26.8 61.3 4c 127 Ac trans-Geranyl CH 2 >100 >100 >100 >100 >100 4d 128 Ac 3-Methyl-2-butenyl CH 2 12.6 7.9 25.7 47.8 >100 4e 131 Ac Dodecyl CH 2 2.0 10.9 10.0 22.1 35.1 8 129 Boc Dodecyl CH 2 15.1 15.5 48.9 64.6 >100 9 252 H.HC Dodecyl CHz- 17.7 12.5 >100 >100 >100 Table 2. Structure and activities of farnesylthio methyl ketone derivatives against Nalm-6 (B-lineage ALL), Molt-3 (T-lineage ALL), BT- 20 (breast cancer), PC-3 (prostate cancer) and U-373 (glioblastoma) cell lines.
0 No. HI n R'IC50 (WM) Number Nalm-6 Molt-3 BT-20 PC-3 U-373 B-lineage T-lineage Breast Prostate Gliobla ALL I ALL Cancer Cancer stoma 3M 84 I CH=N 2 >100 60.3 >100 >100 >100 3g 83 2 CH=N 2 53.5 6.8 >100 >100 >100 Mf 126 1 CH 2 -CI 84.3 >100 >100 >100 >100 4g 125 2 CH 2 -CI 40.7 35.5 >100 >100 >100 Table 3. Comparison of the effect of the S-alkyl chain length upon the activities of cysteine chloromethyl ketone derivatives against Nalm-6 (B-lineage ALL) and Molt-3 (T-lineage ALL), (breast cancer), PC-3 (prostate cancer) and U-373 (glioblastoma) cell lines SUBSTITUTE SHEET (RULE WO 00/00469 WO 0000469PCT/UJS99/I 4758 H0 R 3
IC
50
(IM)
Nalm-6 B-lineage AT T Molt-3 T-lineage AT II BT-20 Breast PC--3 Prostate U-373 Glioblastomna Cancer Cancer 314 Methyl 315 Ethyl 369 Propyl 363 Butyl 224 Pentyl 357 Hexyl 263 Heptyl 352 Octyl 364 Nonyl 371 Decyl 321 Undecy 131 Dodecy 323 Tridecy 354 Tetrade cyl 225 Pentad ecyl 366 Hexade cyl 370 Octade cyl 226 Eicosyl 322 Docosy 30.3 52.8 6.9 41.4 5.8 3.3 4.8 5.6 7.3 4.7 1.7 2.0 >100 8.7 8.9 16.0 >100 >100 >100 80.8 99.9 8.0 5.6 5.4 0.7 2.5 4.1 6.7 3.4 3.0 10.9 >100 8.8 8.6 17.3 >100 >100 >100 >100 96.4 >100 >100 89.5 >100 84.9 58.8 100 >100 99.1 10.0 >100 >100 >100 >100 >100 >100 >100 >100 41.2 37.7 >100 >100 25.1 31.3 35.4 96.3 >100 64.7 22.1 >100 54.8 >100 >100 >100 >100 >100 >100 >100 97.7 86.9 >100 91.9 62.6 >100 88.2 86.2 56.7 35.1 >100 >100 >100 >100 >100 >100 >100 SUBSTITUTE SHEET (RULE WO 00/00469 WO 0000469PCTIUS99/14758 42 Table 4. Examination of the effect of changing R1 of the molecule.
H
3 C 'JN H of HI No. R1ICso0 Wj) Nalm-6 Molt-3 BT-20 PC-3 U373 131 CH,-CI 2.0 2.3 10.0 22.1 35.1 348 CH=N 2 15.4 22.9 97.9 >100 >100 488 CH 2 -Br 1.3 3.19 33.83 39.6 22.5 208 OH 508 CH 2 -O-CO-Ph 267 N(OCH 3
)CH
3 50.1 >100 >100 >100 274 H 12.6 13.1 22.8 >100 269 CH 2 ,-S-Ph >100 >100 >100 >100 >100 302 CH 2 -S-2-naphthyl >100 >100 >100 >100 >100 399 CH 2
-S-C
6
F
5 91.2 40.8 >100 91.6 >100 365 CH,-S-trityl 93.1 97.3 >100 >100 >100 273 CH 2
-S-CH
2
CH
2 44.4 50.3 20.06 >100 >100 C0 2
H
SUBSTITUTE SHEET (RULE 26) WO 00/00469 WO 0000469PCT/US99/I 4758 43 Table 5. Examination of the effect of changing X from S to 0 and altering R4.
x RN f
CI
0 HI R 4 X ICSO (PiM) No. Nalm-6 Molt-3 BT-20 PC-3 U373 252 H.HC1 5 17.7 12.5 >100 >100 >100 131 Acetyl S 2.0 2.3 10.0 22.1 35.1 489 Acetyl 0 3.8 15.3 >100 >100 >100 490 Trifluoroacetyl 5 32.6 41.3 >100 >100 >100 129 t-Butyloxycarbonyl 5 15.1 15.5 48.9 64.6 >100 266 t-Butyloxycarbonyl 0 64.5 49.9 37.1 319 Etljyloxycarbonyl S 77.6 84.2 >100 >100 >100 413 Propyloxycarbonyl s 320 Benzyloxycarbonyl 5 13.5 >100 >100 >100 >100 398 9- S 25.7 32.3 >100 >100 >100 Fluorenymcthyloxycarbonyl 491 Benzoyl S 5.4 6.5 >100 52.1 >100 268 3-Dimethylamiiobenzoyl 5 96.1 >100 >100 >100 Table 6. An examination of the effects of incorporating rings and branched chains into R3.
x 0
Z
H
3 C J N v CI H 0 SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 44 HI No. R 3 IC5o (PM) Nalm-6 Molt-3 BT-20 PC-3 U373 419 Allyl 4.3 7.3 55.7 >100 56.7 400 349 t-Butyl 71.0 71.9 >100 >100 >100 391 2-Methylpropyl 421 2,2-Dimethylpropyl 388 t-Butylthio 387 3-Methylbutyl 390 2-Ethylbutyl 507 Cyclopropylmethyl 385 Cyclobutylmethyl 386 Cyclohexylmethyl 251 Benzyl 351 4-Methoxybenzyl 60.17 4.75 73.1 43.8 45.6 389 Benzyloxycarbonyl 1.2 3.5 49.3 23.4 54.4 418 Diphenylmethyl 350 Trityl 10.0 26.4 88.8 52.2 87.1 392 2-Naphthylmethyl 2.6 2.9 40.4 36.6 41.8 420 2-Anthraquinonylmethyl The data shown in Table I suggest that substitution at the R1 position with a chloromethyl group is better than substitution with a diazomethyl group. Placement of the dodecyl and famesyl groups at the R3 position produced compounds having the greatest cytotoxicity.
The effect changing the length of R 2 are reported in Table 2. Omission of the sidegroup caused the cytotoxicity of the compounds to decrease. Additionally, compounds where R 2 comprises two carbon atoms were more cytotoxic than compounds A series of compounds was prepared with different aliphatic chain lengths in the R 3 position to determine the effect of chain length on cytotoxicity. As shown in Table 3, compounds with chain lengths of about 5 to 15 were the most effective anti-cancer agents. Preferred lengths were chain lengths of about 11 to 12.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 Various groups were tested in the R' position to further define effective anticancer compounds. The results are reported in Table 4. Substitution of a bromomethyl group at the R' position produced the most effective compound, consistent with Table I where chloromethyl was the most effective compound.
The effect of changing of X and R 4 on cytotoxicity was examined and reported in Table 5. The data show that a small acetyl substituent as R 4 produces a potent cytotoxicagent, as both absence of acetyl and substitution with a larger group caused a loss in potency. Substitution of R 4 with benzoyl produced an effective compound. The effect of changing X to O is more complex, with the derivatives being comparable in some cell lines but different in others. The ether compounds may offer advantages in terms of stability, despite their lower cytotoxic potency.
Various substitutions of R 3 were analyzed to determine the effects of branched and ring structures on cytotoxicity. The results demonstrate that ringed and branched structures are effective anti-cancer compounds.
Example 4 Cytotoxicity of HI-131 in Primary Cancer Cells The cytotoxicity of HI-131 against primary cancer cells was evaluated in leukemia cells taken from six children (Figure IA), using the MTT assay described for Example 3. The cells were exposed to HI-131 at concentrations ranging from 0 to 50 p.M. Percent survival was calculated as described for Example 3 and plotted against the HI-131 concentration used in the experiment. A composite concentration survival curve was then prepared from the data (Figure 1B).
The results clearly show a dose dependent cytotoxic effect of HI-131 in primary cancer cells taken from all six patients.
Example HI-131 Induces Apoptosis of Leukemia Cells The ability of HI-131 to induce apoptosis cells was evaluated in human leukemia in NALM-6 cells and primary leukemic cells from 2 patients. Cells were treated with 50 pM compound HI-131 for 24 hours. After incubatin, the cells were SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 46 harvested and analyzed for apoptosis by in situ TUNNEL analysis and confocal laser scanning microscopy as described in Sudbeck et al., 1999, Clin. Cancer Res., 5:1589-82. Controls were treated with vehicle alone.
The data are shown in Figures 2A-2F. Controls (Figures 2A, 2C, and 2E) failed to induce apoptosis. In contrast treatment with HI-131 (Figures 2B, 2D, and 2F) greatly induced apoptosis in the NALM-6 and primary leukemic cells.
Induction of apoptosis was further evaluated in primary leukemic cells and established NALM-6 and MOLT-3 cell lines following treatment with HI-131.
Data are shown in Figure 3.
Primary leukemia cells treated with vehicle alone typically displayed an apoptotic rate of approximately 25%, with one sample exhibiting the much higher rate of about 70%. The rate of apoptosis in the control treated NALM-6 and MOLT-3 cell lines was much lower at about The rate of apoptosis in all but one of the primary leukemic cell samples increased dramatically after treatment with HI- 131 with an approximately 4-fold induction of apoptosis being typical. HI-131, induced apoptosis was much more dramatic in NALM-6 and MOLT-3 cells, with an approximately 20-fold induction of apoptosis.
Example 6 HI-131 Inhibits Tumor Cell Invasion The ability of HI-131 to inhibit invasion by MDA-MB-231 breast cancer cells and U373 glioblastoma cells was evaluated.
Cell Invasion Assay The in vitro invasiveness of MDA-MB-231 breast cancer cells and U373 glioblastoma cells was assayed using a previously published method which employs Matrigel-coated Costar 24-well transwell cell culture chambers ("Boyden chambers") with 8.0-.tm-pore polycarbonate filter inserts (Albini, et al., 1987, Cancer Res., 47:3239-3245). The chamber filters were coated with 50 tg/ml of SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 47 Matrigel matrix, incubated overnight at room temperature under a laminar flow hood and stored at 4 0 C. Matrigel matrix is made up of several components of the extracellular matrix (ECM), including collagens, laminin and proteo-glycans.
On the day of the experiment, the coated inserts were rehydrated with 0.5 ml serum-free DMEM containing 0.1% bovine serum albumin for 1-2 hours. To study the effects of HI-131 on invasiveness of glioblastoma and breast cancer cells, exponentially growing cells were incubated overnight with HI-131 at various concentrations ranging from 1 uM to 25 iM and 2.5 jpM to 25 uM, respectively. The cells were trypsinized, washed twice with serum-free DMEM containing BSA, counted and resuspended at 1 x 105 cells/ml. 0.5 ml cell suspension containing 5 x 104 cells in a serum-free DMEM containing HI-131 or vehicle was added to the Matrigel-coated and rehydrated filter inserts. Next, 750 ul ofNIH fibroblast conditioned medium was placed as a chemoattractant in 24-well plates and the inserts were placed in wells and incubated at 37 0 C for 48 hours. After the incubation period, the filter inserts were removed, the medium was decanted off and the cells on the top side of the filter that did not migrate were scraped off with a cotton-tipped applicator. The invasive cells that migrated to the lower side of the filter were fixed, stained with Hema-3 solutions and counted under microscope.
Five to 10 random fields per filter were counted to determine the mean values for the invasive fraction. The invasive fractions of cells treated with HI-131 were compared to those of DMSO treated control cells and the percent invading relative to the control was determined using the formula: Invading 100 Number of Adherent Drug Treated Cells Number of Adherent Control Cells Each treatment condition was evaluated in duplicate in 3 independent experiments. IC 50 values were calculated by non-linear regression analysis using Graphpad Prisin Software Version 2.0 (Graphpad Software Inc., San Diego, CA).
Results As shown in Figures 4 and 5, MDA-MB-231 breast cancer cells and U373 glioblastoma cells were highly invasive in Matrigel-coated Boyden chambers. HI- SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 48 131 inhibited the invasion of both MDA-MB-231 breast cancer cells and U373 glioblastoma cells through the Matrigel matrix in dose-dependent fashion.
Example 7 HI-131 Inhibits Adhesion of Cancer Cells The ability of HI-131 to inhibit adhesion of MDA-MB-373 and U373 Glioblastoma cells was evaluated.
During the multistep process of tissue invasion, tumor cells initially adhere to the extracellular matrix proteins via cell surface integrin receptors and then gain migratory capacity to enter the surrounding tissues. ECM proteins such as laminin, fibronectin, and type IV collagen are thought to play an important role in tumor cell attachment and migration. Laminin, fibronectin and collagen have been found in the basal lamina of blood vessels and in the glial limitans extema in the brain that promote the adhesion and invasion of tumor cells in situ (Carbonetto, 1984, Trends Neurosci., 7:382-387; Rutkaet al. J. Neurosurg., 69:155-170; Venstrom, et al, 1993, FASEB 7:996-1003). The effects of these ECM proteins on integrinmediated U373 glioblastoma and MDA-MB-231 cell adhesion was examined.
Cell Lines A human brain tumor cell line derived from an adult patient with glioblastoma, U-373 MG (Cat. #HTB-17) and MDA-MB-231 breast cancer cells (Cat. #HTB-26) were obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in liquid culture using DMEM supplemented with fetal bovine serum and antibiotics. Fibroblast conditioned medium was used as a source of chemoattractant in vitro invasion assays. Conditioned medium was prepared as described previously (Albini, et al., 1987, Cancer Res., 47:3239-3245).
For the preparation of this conditioned medium NIH/3T3 embryonic fibroblasts (ATCC cat. #CRL-1658) were grown to 80% confluency in DMEM medium supplemented with 10% FBS and cultured for 24 hours in serum-free medium containing 0.5 vg/ml bovine serum albuminutes The culture supernatants were collected, centrifuged at 1000 x g for 15 minutes to remove cellular debris and used as conditioned medium.
SUBSTITUTE SHEET (RULE 26) WO 00/00469 PCT/US99/14758 49 Adhesion Assays In vitro adhesion assays were performed to study the baseline adhesive properties of U373 glioblastoma and MDA-MB-231 breast cancer cells and (b) evaluate the effects of HI-131 on the adhesive properties of these cells. The plates for the adhesion assays were precoated with the extracellular matrix proteins laminin, fibronectin or type IV collagen (each at a final concentration of 1 j g/ml in PBS) overnight at 4°C and dried. On the day of the experiment, the wells were rehydrated and blocked with 10% bovine serum albumin in PBS for 1 hour at room temperature and used for the adhesion assays, as described below.
To study the effects of HI-131 on glioblastoma and breast cancer cell adhesion, exponentially growing cells in DMEM were incubated with the compound HI-131 or with genistein at concentrations ranging from 10 a.M to 50 4M and 5 uM to 25 M respectively for 16 hours in a humidified 5% CO 2 atmosphere. DMSO was included as a vehicle control. After treatment, cells were detached from the flasks with 0.05% trypsin (Life Technologies) resuspended in DMEM, incubated at 37 0 C for 2 hours to allow them to recover from the trypsinization stress and examined for their ability to adhere to plates precoated with ECM proteins.
In adhesion assays, cells were centrifuged, washed twice with serum-free DMEM, counted and resuspended in serum-free DMEM to a final concentration of 2.5 x 105 cells/ml. One hundred jl of the cell suspension containing 2.5x 10 4 cells were added to each well and cells were allowed to adhere for 1 hour at 37 0 C in a humidified 5% CO 2 atmosphere. The adherent fraction was quantitated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays. In brief, after washing the wells, 10 pl1 of MTT (0.5 mg/ml final concentration) (Boehringer Mannheim Corp., Indianapolis, IN) was added to each well and the plates were incubated at 37 0 C for 4 hours to allow MTT to form formazan crystals by reacting with metabolically active cells. The formazan crystals were solubilized overnight at 37 0 C in a solution containing 10% SDS in 0.01 M HC1. The absorbance of each well was measured in a microplate reader (Labsystems) at 540 nm and a reference wavelength of 690 nm. To translate the OD 5 40 values into the number of cells in each well, the OD 540 values were compared to those on standard OD 5 40 -versus-cell number curves generated for each cell line. The adherent fraction of cells treated SUBSTITUTE SHEET (RULE 26) with HI-131 was compared to the DMSO-treated control cells and the percent adhesion relative to the control was determined.
Each treatment condition was evaluated in duplicate in 3 independent experiments. The ICso values were calculated by non-linear regression analysis.
Results As shown in Figures 6 and 7, control U373 glioblastoma cells adhered to plates precoated with laminin, fibronectin, or type IV collagen about equally.
Similar results were obtained with MBA-MD-231 breast cancer cells. Treatment with HI-131 resulted in a dose-dependent loss of adhesion in both glioblastoma and breast cells (See Figures 6 and 7).
All publications, patents, and patent documents described herein are incorporated by reference as if fully set forth. The invention described herein may be modified to include alternative embodiments. All such obvious alternatives are within the spirit and scope of the invention. as claimed below.
Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
9..
9* *9 9 00•00

Claims (18)

1. A compound of formula 11: R 3 R R 1 HN Rx 4 wherein X is 0 or S; R' IS (C 1 C 3 1) haloalkyl or C 3 diazoalkyl; R 2 is alkylene; ~.R 3 i (C 1 C 3 alyl, C O C haloalkyl, (C 1 C 30 alkenyl, (C 1 C 30 *haloalkenyl, C 2 cycloalkyl, C 2 cycloalkenyl, C,,)aryl, anthroquinonylmethyl, naphthylmethyl, or C, R" 1 is independently (C 1 C 3 alkyl, C 30 haloalkyl, C 30 alkenyl, or C 30 haloalkenyl; R 12 is aryl substituted methyl; R 4 is H, -C(0)R 3 or 14 R" 3 and R" 4 are each independently C 12 alkyl, C,) haloalkyl, (C, 1 C,2) alkenyl, C,2) haloalkenyl, (C 3 C 12 cycloalkyl, or C 3 -C 1 ,)cycloalkenyl; or (C C12 *a pharm-aceutically acceptable acid addition salt thereof; with the proviso that a compound of formula 11 excludes N-Boc-S-all -trans- farnesyl- L-cysteine diazomethyl ketone and N-Boc-S-all -trans- famesyl-L-cysteine chloromethyl ketone.
2. A compound of formula III: H 3 C N H 0(I) wvherein R' is H, hydroxyl, C 30 alkyl, C,, 0 alkenyl, C 30 haloalkyl, C 30 diazoalkyl, -CH, -NR 6 or -CH, -S-R' wherein R 5 is independently aryl, Cj 0 alkyl, C 30 haloalkyl, (Cl CJ 0 alkenyl, (C 1 CO 0 diazoalkyl, C, 4 cycloalkyl, or :cycloalkenyl, Ris independently H, (C 1 C 3 alkyl, C 30 haloalkyl, :C, 30 diazoalkyl, (C 1 C 3 alkenyl, (C 1 haloalkenyl, C,) cycloalkyl, or C2 4 cycloalkenyl; R 7 is -OR', R' is independently C, 30 alkyl, CO 0 haloalkyl, C 30 diazoalkyl, CJ 0 alkenyl, C 30 haloalkeniyl, cycloalkyl, or (C 1 cycloalkenyl; R. 9 is independently C 30 alkyl, C 30 haloalkyl, (C 1 CM 0 diazoalkyl C 3 )aknl C CO 0 haloalkenyl, C2 4 cycloalkyl, (C 1 C1 4 cycloalkenyl, or -R' 0 C0 3 H; R 10 is C 30 alkyl or C 30 alkenyl; and R 2 is (Cr- C2) alkylene; or a pharmaceutically acceptable acid addition salt thereof.
3. A compound of the formula IV: sR2 R 0 (TV) w~herein R1 is H, C 30 alkyl, CO 0 alkenyl, -C 30 haloalkyl, C 30 diazoalkyl, -CH, O-C(O)R 5 ,-RRo 9 R 5 is independently aryl, C 3 alkyl, C 3 haloalkyl, C 30 alkenyl, C 30 )diazoalkyl, cycloalkyl, or cycloalkenyl; R 6 IS independently H, -CO 0 alkyl, -CO 0 haloalkyl, C 30 dia-zoalkyl, C 30 alkenyl, C 30 haloalkenyl, C 2 cycloalkyl, or cycloalkenyl; R 7 is -OR'; -R8 is independently -C 30 alkyl, C 30 haloalkyl, C., 0 diazoalkyl, CO 0 alkenyl, C 30 haloalkenyl, cycloalkyl, or cycloalkenyl; R' is independently C 30 alkyl, (CI CA 0 haloalkyl, C 30 diazoalkyl, C 30 alkenyl, haloalkenyl, cycloalkyl, cycloalkenyl, or -R' 0 C0 2 H; 0 is alkyl or -CM 0 alkenyl; and R. 2 Is (C,-C 2 alkylene; or a pharmaceutically acceptable acid addition salt thereof.
4. The compound of claim 1, 2, or 3, wherein R' is a C 3 haloalkyl. The compound of 1, 2, or 3, wherein R' is a C 30 chioroalkyl.
6. The compound of claim 4, wherein R1 is chioromethyl or bromomethyl. 54
7. The compound of claims 1, 2, or 3, wherein R' is (CI C~ 0 diazoalkyl. S. Thc compound of claim 7, wvherein R' is diazornethyl.
9. The compounid of claim 1, wherein R' 3 is alkyl. Thle compound of claim I Wherein R, is Selected froml thle group consisting of:. acotyl, BOC, and BOC amino acid. II., Thc compound of caM 10, wheryin said amin acid is Clycine..
12. The compound of claim wherein is imethyl or etyl.
13. The compound ofdcaim 1, wherein it' is haloalkyl, R- is C2) alk\'lenc, Ris(C,-C:3C 1 aky Yl and RW -COCI.,
14. The compound of claim 13, w hercin RI is chioroalkyl or bronloalkvl.
15. The conmound ofdcaim 13, wherein W is chloromethyl or hromomethyl.
16. Thc compound ofdclim B3, wherein R' 3 is (CQ) alkyl. T 7 The compound of cla m I or 2, havi ng (he structure o f N- Ac-",-codecyl- cys chlIoromethyl keton e (HI- 131); or a ph arm aceut icall1y accep table a, dit ion sail1 1 8. A pharmaccutical composition comp rising a. therapeuLtical Iv cf'fcctivc amount of a comnpound of claims 1, 1 or 3 and a pharmnaceutically accputbl carrier .0 or diluent. A method for inhibIng, growth, of tumor cells in a subject comprising admintring to said subject a compouind of claimls 1, 2, or 3. The Mod of clam 19, wherein said inhibiting comprises inducing apoptosisof saitumor cls.
21. A method of treating cancer in a subject comprising administeringr to said subject a compound of claims 1, 2, or 3. 2.The method of claim 21, wherein said cancer is leukemia, breast cancer, prostate cancer, or brain tumnor. 23 A method for inducing cytotoxicity in a cell comprising administering to said cell a cy-totoxic dose of the compound of claims 1, 2, or 3.
24. The method of claim 23, wherein said cell is a cancer cell. The method of claim 21, wherein said compound is: N-Ac-S-tu-anis-tr-ans-fai-niesyl-Cys diazomethyl ketone (111-3 67);l N-Ac-S-t7-ans-trrans-famesyl-Cys chioromethy] ketone (HI-36S); N-Ac-S-trans-geranyl-Cys diazomethyl ketone (HI- 122); N-Ac-S-trans-geranyl-Cys chloromnethyl ketone (HI-I 27); N-Ac-S-(3)-methyl1-2-butenyl)-Cys diazomethyl ketone (HI- 123); N-Ac-S-(3)-methyl-2-butenyl)-Cys chloroinethyl ketone (HI-I 28); N-Ac-S-dodecyl-Cys diazomethyl ketone (1-1-348); N-Ac-S-dodecyl-Cys chloromethyl ketone (Hi- 13 1); N-Boc-S-farnesyl-Cys di azoniethyl ketone (HI-82);- N-Boc-S-famesyl-Cys chloromethyl ketone (HI- 124);l S-trains-tr-ans-Famesyl-mercaptoethy diazomethyl ketone S-ir-ans-tr-ans-Fanesyl-2mercaptomethiyl chloromethiyl ketone (1-1-125); S-tran-tran-F-iai-ai-amesyl-ptmtyl diazomethyl ketone (HI-4); -Bran-tran-F-iai-ai-amesyl-ptmtyl chloromethyl ketone (HI- 126 N-Boc-S-doeyl -cys] choromethyl ketone (HI-1); N-Ac-S-ethyl-cystene chloromethyl ketone (HI-31 N-Ac-S-ethyl-cysteine chloromethyl ketone (HI-3 N-Ac-S-butyl-cysteine chiorornethyl ketone (HI-363); N-Ac-S-pentyl-cysteine chiorornethy] ketone (HI-224); N-Ac-S-hexyl-cysteine chiorornethyl ketone (111-35 7); N-Ac-S-heptyl-cysteine chiorornethyl ketone (111-263 N-Ac-S-octyl-cysteine chioromethyl ketone (HI-352); N-Ac.-S-nonyl-cysteine chiorornethyl ketone (HI-3 64); N-Ac-S-decyl-cysteine chioromnethyl ketone (HI-3 71); N-Ac-S-undecyl-cysteine chiorornethyl ketone (HT-32 1); N-Ac-S-tridecyl-cysteine chiorornethyl ketone, (111-323); N-Ac-S-tetradecyl-cysteine chiorornethyl ketone (111-354); N-Ac-S-pentadecyl-cysteine chioromethyl ketone (HI-225); N-Ac-S-hexadecyl-cysteine chiorornethyl ketone (141-366); N-Ac-S-octadecyl-cysteine chioromethyl ketone (111-370); N-Ac-S-eicoyl-cysteine chlorornethyl ketone (111-226);, N-Ac-S-docosyl-cysteine chioromethyl ketone (111-322); N-Ac-S-al lyl-cysteine chiorornethyl ketone (HJ-4 19); ~~~N-Ac-S-t-butyl-cysteine chloromethyl ketn H-4) I -*oe H-390 N-Ac-S-2-methylpropyl-cysteine chiorornethyl ketone (111-391); N-Ac-S-2,2-dimetlhylpropyl-cystelie chiorornethyl ketone (1-1-421); N-Ac-S-3-rnethiylbutyl-cysteine chiorornethyl ketone (141-387); N-Ac-S-2-ethylbutyl-cysteiine chiorornethyl ketone (141-390); *N-Ac-S-cyclopronvlmetliy1-cysteine chlorornethyl ketone (HI-501)-; N-Ac-S-cyclobutylmethiyl-cysteine ciorornethyl ketone (1-1-3 N-Ac-S-cyclohexylmethyl-cysteine chioromethyl ketone (HI-386); Si....N-Ac-S-benzyl-cysteine chioromethyl ketone (11-25 1); N-Ac-S-4-methoxybenzy]-eysteine chiorornethyl ketone (HI-349); N-Ac-S-benzyloxycarbonyl-cysteiine chioromethyl ketone (111-389); N-Ac-S-diphenylrnethyl-c),steine chioromethyl ketone (111-41 8); N-Ac-S-trityl-cysteine chioromethyl ketone (HI-350); N-Ac-S-2-naphthylmethyl -cysteine chioromethyl ketone (111-392); N-Ac-O-dodecyl-serine chiorornethyl ketone (HI-489); N-Boc-O-dodecyl senne chioromethyl ketone (HI-266); N-Propyl oxycarbonyl-S-dodec)yl-cysteine chioromethyl ketone (HI-41 3); N-Benzyloxycarbonyl-S-dodecyl-cysteine chioromethyl ketone (HI-320); N-9-Fluorenylm ethyl ox ycarbonyl -S -dodecyl-cysteine chiorornethyl ketone (HI1-39S); N-3 -Di1rn ethyl aminobenzoyl-S -dodecyl-cysteine chioromethyl ketone (HI- 268); N-Ac-S-dodecyl-cysteine bromrnethyl ketone (HJ-48 S); N-Ac- S-dodecyl-Cys-H (HI-274); N-Ac-S-dodecyl-Cys-CH2-SPh (HJ-269); N-Ac-S-dodecyl-Cys-CH2-S-2-naphthyI (111-3 02); N-Ac-S-dodecyl-Cys-CH9-S-CH2C1] 2C02H (HI-273).
26. A compound of the formiula: *N-Ac-S-trranis-tr-ans-famesyl-Cys diazomnethyl ketone (HI-367); N-Ac-S-tr-ans-t;rans-farnesyl-Cys chiorornethyl ketone (1-1-368);- N-Ac-S-trans-g eranyl-Cys diazornethiyl ketone (HI- 122); eve: N-Ac-S-trans-geranyl-Cys chloromiethiyl ketone (HI- 12 7); N-Ac-S-(3-methyl-2-buteniyl)-Cys diazomnethyl ketone (HI- 123); ethyl -2 -butenyl)-Cys chiorornethyl ketone (HI- 128); N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348); N-Ac-S-dodecyl-Cys chioromnethyl ketone (HI- 131);- **S-tr-ans-tr-ans-Fanesyl-mercaptoethiyl di azomethyl ketone (HT-83); Poo* S-tr-ans-ti-ans-Famesyl-2mercaptomethyl chioromethy] ketone (HI- 125); N-Boc-S-dodecyl-Cys chioromethyl ketone (1-1-129); S-Dodecyl-Cys chioromnethy l ketone hydrochloridle (HI-25 2); N-Boc-Gly-S-tirans-tr-ans- famesyl-Cys diazornethyl ketone (1-1-40 1); N-Boc-Gly-S-tzrans-tr-ans-fanesyl-Cys chioromethyl ketone (HI-I 3 0); N-Ac-S-methyl-cysteine chioromethyl ketone (HI-3 14); N-Ac-S-ethyl-cysteine chlorornethyl ketone (HI-3 N-Ac- S-prop yl-cysteine chioromethyl ketone (HI-369); N-Ac-S-butyl-cysteine chiorornethyl ketone (HJ-363)); N-Ac-S-pentyl-cysteine chioromethyl ketone (HI-224);- N-Ac-S-hexyl-cysteiine chiorornethyl ketone (HI-35 7); N-Ac-S-heptyl-cysteine chlorornethyl ketone (HI-263);- N-Ac-S-octyl-cysteine chiorornethyl ketone (HI-3 52); N-Ac-S-nonyl-cysteine chiorornethyl ketone (HI-364); N-Ac-S-decyl-cysteine chiorornethyl ketone (HI-3 7 1); N-Ac-S-undecyl-cysteine chioromethyl ketone 2 1); N-Ac-S-tridecyl-cysteine chioromethyl ketone (HI-3 23); N -Ac-S -tetrad ecyl -cystei ne ciorornethyl ketone (HI-3 54); N-Ac-S-pentadecyl-cysteine chioromethyl ketone (HI-225); N-Ac-S-hexadecyl-cysteiine chioromethyl ketone (HI-366)-; N-Ac-S-octadecyl-cysteine chiorornethyl ketone (Hl-3 0:06 N-Ac-S-eicoyi-cysteine chlorornethyl ketone (HI-226)-; 0% C. CN-Ac-S-docosyl-cysteine chioromethyl ketone (HI-3 22); 0:69N-Ac-S-allyi-cysteine chiorornethyl ketone (HI-4 19); N -Ac-S-t-butyl-cysteine chiorornethyl ketone (HJ-349); N-Ac-S-2 -methylpropyl-cysteine chiorornethyl ketone (HI-3 91);l S N-Ac-S.-2,2-diimethylpropyl-cysteinie chloromethyl ketone (HI-42 1); :.:~N-Ac-S-3methylbutyl-cysteine chi'orornethyl ketone (HI-3 87);l S N-Ac-S-c-ylbutylmty-cysteine choromethyl ketone (H N-Ac-S-cyclopropylmethyl-cysteine chioromethy] ketone (HI-S 0); N-Ac-S-cylouyrthyl-cysteine choromethyl ketone (HI-3 8); N-Ac-S-cyclheylrehyl-cysteine choromethyl ketone (HI-18); N-Ac-S-benyl-cysteine choroiethyl ketone (HI-5 N-Ac-S-2-naplhthylrncthiyl-cysteinie chiorornethyl ketone (1-11-392); N-Ac-O-dodecyl-scrine chioromethyl kctonc (HI1 -489); N-Boc-O-dodecyl serine chlor-orncthyl ketotie (HI1-206); N-P r-opyloxycarboniyl-S-dodccyl-cystciic ciorornethl vketone 1-413);, N-Beinzyloxycarbonyl-S-dodccyl-cysteine chiorornethyl ketone (H 1-32U): N-9-1-Luorenlylnethiyloxycarbonyl-S-dodlcvl-cystcince chloromicthyl kctoiio (HI-3)98)-, N-3-D i methiylainiobenizoyl-S-dlodecyl -cysteine chioroineth% I kcloiie (1-11 268); N-Ac-S.-dodecyl-cysteine bromionethyl ketone (111488); N-Ac-S-dlodccyl-Cys-.H (H-11-74); N-Ac-S-dodecy-Cys-C-1?-SPh (HI-269); I\-Ac-S -clod ccy]-Cys-C II)-S -2-n afh thyl (1-1-302); or N-Ac-S-dodecy]-Cys-Cl9-S-CHCH9 CO-1E (HI-273).
27. A compound according to claim 1 substantially as herein before described with reference to the examples.
28. A pharmaceutical composition comprising a compound according to claim 27 and a pharmaceutically acceptable carrier or diluent substantially as herein before described with reference to the exam-ples.
29. *A method according to any of claims 19, 21 or 23 substantially as herein before described with reference to the examples. 0 OV, DATED this TENTH day of SEPTEMBER 2002 Parker Huahes Institute Applicant Wray Associates Perth, Western Autralia Patent Attorneys for the Applicant.
AU48459/99A 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents Ceased AU754086B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9099798P 1998-06-29 1998-06-29
US60/090997 1998-06-29
US9736398P 1998-08-21 1998-08-21
US60/097363 1998-08-21
PCT/US1999/014758 WO2000000469A2 (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents

Publications (2)

Publication Number Publication Date
AU4845999A AU4845999A (en) 2000-01-17
AU754086B2 true AU754086B2 (en) 2002-11-07

Family

ID=26782863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48459/99A Ceased AU754086B2 (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents

Country Status (5)

Country Link
EP (1) EP1091934A2 (en)
JP (1) JP2002519341A (en)
AU (1) AU754086B2 (en)
CA (1) CA2336108A1 (en)
WO (1) WO2000000469A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1091948B9 (en) * 1998-06-29 2003-09-10 Parker Hughes Institute Tubulin binding compounds (cobra)
US6258841B1 (en) 1998-06-29 2001-07-10 Parker Hughes Institute Tubulin binding compounds (COBRA)
NO328803B1 (en) * 2000-03-03 2010-05-18 Thia Medica New fatty acid analogues
US7214831B2 (en) 2002-05-22 2007-05-08 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
US6734207B2 (en) 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
PT2362866E (en) * 2008-11-11 2015-10-26 Signum Biosciences Inc Isoprenyl compounds and methods thereof
US9630937B2 (en) * 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
JPH05117169A (en) * 1991-10-29 1993-05-14 Mitsubishi Kasei Corp Production method of chloromethyl ketone
US5616485A (en) * 1993-12-23 1997-04-01 Cangene Corporation Streptomyces proteases and improved streptomyces strains for expression of peptides and polypeptides
US6180402B1 (en) * 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor

Also Published As

Publication number Publication date
CA2336108A1 (en) 2000-01-06
WO2000000469A3 (en) 2000-06-15
JP2002519341A (en) 2002-07-02
EP1091934A2 (en) 2001-04-18
AU4845999A (en) 2000-01-17
WO2000000469A2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
CN100393698C (en) Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them
US20090264487A1 (en) Hemiasterlin analogs
US6734207B2 (en) Cytotoxic compounds
CN101478962A (en) Novel CXCR2 inhibitors
JP2002537286A (en) Thioamide derivative
AU754086B2 (en) Alkyl ketones as potent anti-cancer agents
US6251882B1 (en) Alkyl ketones as potent anti-cancer agents
JP4933683B1 (en) Novel retinoid derivatives having cytotoxic and / or anti-angiogenic properties
CN106536478A (en) Omega-3 analogues
FI113167B (en) Process for the preparation of useful N - [(4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracenyl) carbonyl] amino acids useful for the treatment of osteoarticular diseases
DE69908756T2 (en) MATRIX metalloproteinase inhibitors
JPH03500880A (en) Renin inhibitors, methods for their production, methods for their use and compositions containing them
CA2008771C (en) Pyridinium nitrate, its production and use
AU636090B2 (en) Esters of 2-arylmethyl-1-naphthol derivatives as 5-lipoxygenase inhibitors
CN108191733B (en) A kind of benzene-pyrrolidine compound, its preparation method and anti-hepatic fibrosis use
HK1034523B (en) Hemiasterlin analogs
HK1161872A (en) New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)